US Clinical Development and Medical Affairs -General Medicine 
AIN457/Secukinumab
Clinical Trial Protocol CAIN457AUS07 / [STUDY_ID_REMOVED]
A randomized, double- blind, placebo -controlled, parallel -
group, multicenter study
 to explore changes in
subcutaneous adipose tissue and modulation of skin 
inflammation after 12 w eeks of treatment w ith secukinumab , 
compared to placebo, and up to 52 w eeks of treatment w ith 
secukinumab in adult patients w ith moderate to sev ere 
plaque psoriasis ( ObePso -S)
Document type: Amended Protocol Version
Version number: v02 ( Clean )
Clinical trial phase: IV
Release date: 23-Feb-2018
Property of Novartis
Confidential
May not be used, divulged, published, or otherwise disclosed
without the consent of Novartis
Clinical Trial Protocol Template Version 3.2 (July 2016)

Novartis Confidential Page 2
Amended Protocol Version 02 (Clean) Protocol No. CAIN457AUS07
Table of contents
Table of contents ................................................................................................................. 2
List of tables ........................................................................................................................ 5
List of figures ...................................................................................................................... 6
List of abbreviations ............................................................................................................ 7
Glossary  of terms ................................................................................................................. 9
Amendment 2 .................................................................................................................... 10
Protocol summary .............................................................................................................. 11
1Introduction ....................................................................................................................... 15
1.1 Background ............................................................................................................ 15
1.2 Purpose .................................................................................................................. 16
2Study  objectives and endpoints ......................................................................................... 17
2.1 Objectives and related endpoints ........................................................................... 17
3Investigational plan ........................................................................................................... 18
3.1 Study  design ........................................................................................................... 18
3.1.1
Screening period (Screening to randomization).................................... 19
3.1.2
Double- blind treatment period (Randomization to Week 12 pre -
dose) ...................................................................................................... 19
3.1.3
Double- blind induction period (Week 12 dose through Week 15 
dose) ...................................................................................................... 20
3.1.4 Open -label treatment period (Week 16 to Week 52) ............................ 20
3.1.5 Follow -up period visit 1 (F1) ................................................................ 20
3.1.6 Control cohort of health y volunteers sub
-study .................................... 21
3.2 Rationale for stud y design ..................................................................................... 22
3.3
Rationale for dose/regimen, route of administration and duration of treatment ....22
3.4 Rationale for choice of comparator ....................................................................... 22
3.5 Purpose and timing of interim anal yses/design adapt ations .................................. 23
3.6 Risks and benefits .................................................................................................. 23
3.6.1 Clinical trials experience 
in plaque psoriasis ........................................ 23
3.6.2 Infections ............................................................................................... 25
3.6.3 Pre-treatment evalu ation for tuberculosis
............................................. 26
3.6.4 Inflammatory  bowel disease ................................................................. 26
3.6.5
Hypersensitivity  reactions ..................................................................... 26
3.6.6 Risk of hy persensitivity  in latex -sensitive I ndividuals ......................... 26
3.6.7 Vaccinations .......................................................................................... 26
4Population ................................ ................................ ................................ .......................... 26

Novartis Confidential Page 3
Amended Protocol Version 02 (Clean) Protocol No. CAIN457AUS07
4.1 Inclusion criteria ................................ ................................ ................................ ....27
4.2 Exclusion criteria ................................................................................................... 27
5Treatment ........................................................................................................................... 29
5.1 Study  treatment ...................................................................................................... 29
5.1.1 Study  drug –secukinumab .................................................................... 30
5.1.2 Control drug 
–placebo .......................................................................... 30
5.1.3 Additional treatment .............................................................................. 30
5.2 Treatment groups ................................................................................................... 30
5.3
Treatment assignment and randomization............................................................. 31
5.3.1
Stratification.......................................................................................... 31
5.4 Treatment blinding ................................................................................................. 32
5.5 Treating the patient ................................................................................................ 32
5.5.1
Patient numbering ................................................................................. 32
5.5.2 Dispensing the stud y drug ..................................................................... 33
5.5.3 Handling of study  and additional treatment .......................................... 33
5.5.4 Instructions for prescribing and taking stud y treatment ........................ 34
5.5.5 Permitted dose adjustments and interruptions of study  treatment ........ 35
5.5.6
Rescue medication ................................................................................ 35
5.5.7 Concomitant treatment .......................................................................... 35
5.5.8
Prohibited medication ........................................................................... 35
5.5.9 Emergency  breaking of assigned treatment code .................................. 37
5.6 Study  completion and discontinuation ................................................................... 37
5.6.1 Study  completion and post -study treatment .......................................... 37
5.6.2 Discontinuation of study  treatment ....................................................... 37
5.6.3 Withd rawal of informed consent ........................................................... 39
5.6.4 Loss to follow -
up .................................................................................. 39
5.6.5 Early study termination by  the sponsor ................................................. 39
6
Visit schedule and assessments ......................................................................................... 40
6.1 Rescreening ............................................................................................................ 40
6.2 Unscheduled visits ................................................................................................. 40
6.3 Information to be collected on screening failures .................................................. 46
6.4 Patient demographics/other baseline characteristics ............................................. 46
6.4.1 Demographics ....................................................................................... 46
6.4.2 Psoriasis history  / Prior psoriasis therapies
........................................... 46
6.4.3 Smoking history .................................................................................... 46
6.4.4 Alcohol use history ............................................................................... 46

Novartis Confidential Page 4
Amended Protocol Version 02 (Clean) Protocol No. CAIN457AUS07
6.4.5 Comorbidities –cardiovascular history ................................................ 47
6.4.6 Relevant medical histor y
/current medical conditions ........................... 47
6.4.7 Prior and concomitant medications ....................................................... 47
6.4.8 Determination of tuberculosis status ..................................................... 47
6.4.9 Other baseline characteristics ................................................................ 48
6.5 Treatment exposure and compliance ..................................................................... 48
6.6 Efficacy .................................................................................................................. 49
49
 
50
50
51
6.6.5 Assessment of total Body Surface Area (BSA) and Psoriasis Area 
and Severit y Index (PASI) .................................................................... 52
6.6.6 Appropriateness of efficacy  assessments .............................................. 54
6.7 Safety ..................................................................................................................... 54
6.7.1 Physical examination ............................................................................ 54
6.7.2 Vital signs .............................................................................................. 55
6.7.3 Height and weight and waist circumference ......................................... 55
6.7.4 Laboratory  evaluations .......................................................................... 55
6.7.5 Pregnancy  and assessments of fertility ................................................. 57
6.7.6 Appropriateness of safety  measurements .............................................. 57
6.8 Other assessments .................................................................................................. 57
7Safety  monitoring .............................................................................................................. 57
7.1 Adverse events ....................................................................................................... 57
7.2 Serious adverse events ........................................................................................... 59
7.2.1 Definition of SAE ................................................................................. 59
7.2.2 SAE reporting
........................................................................................ 60
7.3 Reporting of stud y treatment errors including misuse/abuse ................................ 60
7.4 Pregnancy  reporting ............................................................................................... 61
8Data review and database management ............................................................................. 61
8.1 Site monitoring ...................................................................................................... 61
8.2
Data collection....................................................................................................... 62
8.3 Database management and quality  control ............................................................ 62
8.4 Data Monitoring Committee .................................................................................. 63
8.5 Adjudicat ion Committee ........................................................................................ 63
9Data analy sis................................ ................................ ................................ ...................... 63

Novartis Confidential Page 5
Amended Protocol Version 02 (Clean) Protocol No. CAIN457AUS07
9.1 Analy sis sets ................................ ................................ ................................ .......... 64
9.2 Patient demographics and other baseline characteristics....................................... 64
9.3 Treatments ............................................................................................................. 64
9.4 Analy sis of the primary  variable(s) ....................................................................... 64
9.4.1 Variable(s) ............................................................................................. 64
9.4.2 Statistical model, hy pothesis, and method of anal ysis.......................... 64
9.4.3 Handling of missing values/ce nsoring/discontinuations ....................... 65
9.4.4 Sensitivity  analy ses............................................................................... 65
9.5 Analy sis of secondary  variables
............................................................................ 65
9.5.1 Efficacy  variables
.................................................................................. 65
9.5.2 Safety
 variables ..................................................................................... 65
66
9.7 Interim anal yses..................................................................................................... 66
9.8
Sample size calculation.......................................................................................... 67
10Ethical considerations ................................ ................................ ................................ ........ 67
10.1 Regulatory and ethical compliance ........................................................................ 67
10.2 Informed consent procedures
................................................................................. 67
10.3 Responsibilities of the investigator and IRB/ IEC.................................................. 68
10.4 Publication of study  protocol and results ............................................................... 68
10.5 Quality  Control and Quality  Assurance ................................................................. 68
11Protocol adherence ............................................................................................................ 68
11.1 Protocol amendments ............................................................................................. 69
12References ......................................................................................................................... 69
13Appendix 1: Clinically  notable laboratory  values and vital signs ..................................... 73
14
Appendix 2: Tuberculosis screening flowchart................................................................. 74
75
16Appendix 4:  Psoriasis Area and Severit y Index (PASI ) and Body  Surface Area 
(BSA) ................................................................................................................................. 78
17Appendix 5:  Sample L og Table ........................................................................................ 79
List of tables
Table 2
-1 Objectives and related endpoints ................................ .......................... 17
Table 3-1 Clinical outcomes at Week 12 in adults with plaque psoriasis in 
Trials 1- 4 .............................................................................................. 25
Table 5-1 Overview of study  treatment ................................................................. 31
Table 5
-2 Prohibited treatment .............................................................................. 36

Novartis Confidential Page 6
Amended Protocol Version 02 (Clean) Protocol No. CAIN457AUS07
Table 6-1 Assessment schedule ................................ ................................ ............. 41
Table 6-2 Assessment schedule for healthy  control cohort................................... 45
51
Table 6
-4 PASI  scoring s ystem............................................................................. 52
Table 7
-1 Guidance for capturing t he study  treatment errors including 
misuse/abuse ......................................................................................... 61
Table 9
-1 Sample size calculations for percentage of patients who have the 
“event” ................................ ................................ ................................ ...67
List of figures
Figure 3-1 Study  design .......................................................................................... 19

Novartis Confidential Page 7
Amended Protocol Version 02 (Clean) Protocol No. CAIN457AUS07
List of abbreviations
AE Adverse Event
ALT Alanine aminotransferase
AST Aspartate aminotransferase
BMI Body Mass Index
CD Cluster of differentiation
CDER Center for Drug Evaluation and Research
CFR US Code of Federal Regulations 
CHMP Committee for Medicinal Products for Human Use
(e)CRF (electronic) Case Report/Record Form
CRO Contract Research Organization
CS Corticosteroids
CSR Clinical Study Report
CT Computerized tomography
CTRD Clinical Trial Results Database 
CVD Cardiovascular disease
DS&E Drug Safety & Epidemiology
DSM Drug Supply Management
EDC Electronic Data Capture
EMA European Medicines Agency
EOT End of treatment
EU European Union
FACS Fluorescence -activated cell sorting
FDA (US) Food and Drug Administration
GCP Good Clinical Practice
GGT Gamma gluta myltranspeptidatse
Hb Hemoglobin
HIV Human immunodeficiency virus
hs-CRP high sensitivity C -reactive protein
HOMA -IR Homeostatic model assessment- insulin resistance
IB Investigator’s Brochure
ICAM Intercellular adhesion molecule
ICH International Conference on Harmonization of Technical Requirements for 
Registration of Pharmaceuticals for Human Use
IEC Independent Ethics Committee
IFU Instructions for Use
IGA mod 2011 Investigator’s Global Assessment modified 2011
IL Interleukin
IUD Intrauterine device
i.v. Intravenous
IRB Institutional Review Board
IRT Interactive Response Technology
LS Lesional

Novartis Confidential Page 8
Amended Protocol Version 02 (Clean) Protocol No. CAIN457AUS07
MedDRA Medical dictionary for regulatory activities 
MRI Magnetic resonance imaging
MTX Methotrexate
OTC Over-the-counter
PASI Psoriasis Area and Severity Index
PC Personal Computer
PET Positron Emission Tomography
PMDA Pharmaceuticals and Medical Devices Agency
PPD Purified protein derivative
PUVA Psoralen ultraviolet A
OC/RDC Oracle Clinical/Remote Data Capture
PET Positron emission tomography
PFS Pre-filled syringe
RT-PCR Reverse transcription -polymerase chain reaction
SAE Serious Adverse Event
s.c. Subcutaneous
SGOT Serum glutamic oxaloacetic transaminase
SGPT Serum glutamic pyruvate transaminase
SOP Standard Operating Procedure
SUSAR Suspected Unexpected Serious Adverse Reactions
TB Tuberculosis
TCS Topical corticosteroids
TD Study Treatment Discontinuation
TH17 T-helper 17 (cells)
TNF Tumor necrosis factor
UV Ultraviolet
UVA Ultraviolet A
UVB Ultraviolet B
VCAM Vascular cell adhesion molecule
WHO World Health Organization 
WoC Withdrawal of Consent

Novartis Confidential Page 9
Amended Protocol Version 02 (Clean) Protocol No. CAIN457AUS07
Glossary  of terms
Control drug Drugs(s) used as a comparator to reduce assessment bias, preserve 
blinding of investigational drug, assess internal study validity, and/or 
evaluate comparative effects of the investigational drug
Dosage Dose of the study treatment given to the patient in a time unit (e.g. 100 mg 
once a d ay, 75 mg twice a day)
Electronic Data Capture 
(EDC)Electronic data capture (EDC) is the electronic acquisition of clinical study 
data using data collection systems, such as Web-based applications, 
interactive voice response sy stems and clinical laboratory interfaces.
EDC includes the use of Electronic Case Report Forms (eCRFs) which are 
used to capture data transcribed from paper source forms used at the 
point of care.
Enrollment Point/time of patient entry into the study at which informe d conse nt must 
be obtained (e.g. prior to starting any of the procedures described in the 
protocol)
Investigational drug The drug whose properties are being tested in the study; this definition is 
consistent with US CFR 21 Section 312.3 and is synony mous with 
“investigational new drug” or “investigational medicinal product.”
Medication number A unique identifier on the label of each investigational drug package
Part A single component of a study which contains different objectives or 
populations within that single study. Common parts within a study are: a 
single dose part and a multiple dose part, or a part in patients/subjects with 
established disease and in those with newly -diagnosed disease.
Patient ID A unique number assigned to each patient upon signing the informed 
consent 
Period A portion of the study which serves a specific purpose. T ypical epochs are: 
screening/recruitment, wash -out, treatment, and follow- up
Randomization number A unique identifier assigned to each randomized patient, corresponding to 
a specific treatment arm assignment
Source Data/Document Source data refers to the initial record, do cument, or primary  location from 
where data comes. The data source can be a database, a dataset, a 
spreadsheet or even hard -coded data, such as paper .
Study drug/treatment Any single drug or combination of drugs administered to the patient as part 
of the required study procedures; includes investigational drug (s), 
placebo/comparator active drug run -ins or background therapy
Variable A measured value or assessed response that is determined in specific 
assessments and used in data analysis to evaluate the drug being tested 
in the study
Withdrawal of consent 
(WoC)Withdrawal of consent from the study is defined as when a patient does 
not want to participate in the study any longer, and does not want any 
further visits or assessments, and does not want any f urther study related 
contact, and does not allow analysis of already obtained biologic material

Novartis Confidential Page 10
Amended Protocol Version 02 (Clean) Protocol No. CAIN457AUS07
Amendment 2
Amendment rationale
The primary  purpose of this amendment is to allow for the enrollment of healthy  volunteers at 
 to actas a control cohort for the purpose of comparing skin, 
adipose tissue,  data/outcomes to the psoriasis patients enrolled in the 
study .  
Additionally , text related to eSource was deleted as it was not used in this study .
At the time of this amendment, all psoriasis patients have been enrolled in the study .
Changes to the protocol
List of abbreviations and Glossary  of terms was updated to rem ove eSource
Section 3.1.6 was added for the control cohort of healthy  volunteers
Table 6-2 Assessment schedule for healthy  control cohort was added
Section 8 and Section 8.1 were updated to remove reference to eSource
Section 8.2 was updated to clarify  that the data collection process is the same for the 
control cohort of healthy volunteers as for the psoriasis patients
Section 9.6 was updated to clarify  responsibility  for certain data analyses and to specify  
where those anal yses will be reported 
Changes to specific sections of the protocol are shown in the track change version of the 
protocol using strike through red font for deletions and red underlined for insertions.
A copy of this amended protocol will besent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee ( IECs) and Health Authorities.

Novartis Confidential Page 11
Amended Protocol Version 02 (Clean) Protocol No. CAIN457AUS07
Protocol summary
Protocol 
numberCAIN457AUS07
Full TitleA randomized, double -blind, placebo -controlled, parallel -group, multicenter study to 
explore changes in subcutaneous adipose tissue and modulation of skin 
inflammation after 12 weeks of treatment with secukinumab, compared to placebo, 
and up to 52 weeks of treatment with secukinumab in adult patients with moderate to 
severe plaque psoriasi s (ObePso -S)
Brief titleStudy to explore the effect of secukinumab ,compared to placebo ,on fat tissue and 
skinin plaque psoriasis patient s
Sponsor and 
Clinical 
PhaseNovartis Pharmaceuticals Corporation
Phase 4
Investigation 
typeDrug
Study typeInterventional
Purpose and 
rationaleSecukinumab targets interleukin 17a (IL-17a) which may play a critical role in the 
pathophysiology of psoriasis.  IL -17 is not established as a fac tor in excess adiposity, 
however reports suggest that obesity may be a driver for the formation of TH17 T-
cells. This study will provide a comparison of secukinumab to placebo with respect to 
skin inflammation as measured by skin exams in comparison to skin biopsies, 
adipose tissue and blood sample analyses.
Primary 
Objective(s) The primary objective of this study is to explore the modulation of subcutaneous 
adipose tissue and skin inflammation from baseline to Week 12 in patients with 
moderate to severe plaque psoriasis treated with secukinumab compared to placebo
Secondary 
ObjectivesTo explore changes in biometric measurements from baseline to Week 12 in 
patients with moderate to severe plaque psoriasis treated with secukinumab 
compared to placebo
To explore the modulation of subcutaneous adipose tissue and skin inflammation 
from baseline to Week 52 in patients with moderate to severe plaque psoriasis 
treated with secukinumab
Study designThis is a randomized, double -blind, placebo -controlled, parallel -group, multicenter 
study in approximately 75 patient s with moderate to severe chronic plaque psoriasis.  

Novartis Confidential Page 12
Amended Protocol Version 02 (Clean) Protocol No. CAIN457AUS07
The patient s will be enrolled from approximately 15sites within the United States.
The study consists five of periods: screening (from 1-4 weeks); a double -blind 
treatment period (12 weeks); a double -blind induction period (4 weeks); an open-
label treatment period (36 weeks) ; and a follow -up period (1 week) .  The total study 
duration is up to 5 7weeks.
At the start of the double -blind treatment period, patient s are randomized in a 2:1 
ratio to one of two treatment groups –secukinumab or placebo. Randomization will 
be stratified by baseline body  weight (<90 kg or ≥90 kg).At the end of the double -
blind treatment period, allpatient s randomized to receive placebo will be switched to 
secukinumab treatment for the remainder of the study.
Lesional (LS)  
will be obtained via 6 mm punch biopsy from all 
patients at three time points:  Baseline, W eek 12, and W eek 52.
PopulationThe study population will consist of approximately 75 male and female patient s at 
least 18 years of age with moderate to severe plaque psoriasis who are candidates 
for sy stemic therapy or phototherapy.
Key Inclusion 
criteria1.Written informed consent must be obtained before any assessment is performed
2.Males and females ≥18 years of age at the time of screening
3.Clinical diagnosis of chronic plaque -type psoriasis at least 6 months prior to 
randomization as determined by patient interview of his/her medical history and 
by confirmation of diagnosis through physical examination by the investigator
4.Moderate to severe plaque psoriasis as defined at baseline by:
o≥10% Body Surface Area (BSA) involvement and
oPASI total score of ≥12 and
oIGA mod 2011 score of ≥3 (based on a scale of 0 -4)
5.Candidate for systemic therap y, defined as having psoriasis inadequately 
controlled by:
oTopical treatment (including topical corticosteroids) and/or
oPhototherapy and/or
oPrevious sy stemic therapy
Key 
Exclusion 
criteriaForm s of psoriasis other than chronic plaque psoriasis
Medication -induced or medication exacerbated psoriasis
Previous exposure to secukinumab or any other biologic drug directly targeting 
IL-17A or IL -17RA receptors
Diagnosis of other active ongoing skin diseases or skin infections (bacterial, 
fungal, or viral), or inflammatory diseases other than psoriasis that may interfere 
with the evaluation of psoriasis
History of an ongoing, chronic or recurrent infectious disease, or evidence of 
tuberculosis infection
Positive serology for human immunodeficienc y virus (HIV), hepatitis B or C 
infection
Pregnant or nursing (lactating) women 

Novartis Confidential Page 13
Amended Protocol Version 02 (Clean) Protocol No. CAIN457AUS07
Study 
treatmentStudy drug:
Secukinumab 150 mg: 1 ml liquid  formulation in a single -use prefilled 
syringe (PFS) for subcutaneous injection
Control drug:
Placebo to secukinumab 150 mg: 1 ml liquid formulation in a single -use 
prefilled syringe (PFS) for subcutaneous injection
Efficacy 
assessmentsModulation of subcutaneous adipose tissue and skin inflammation
 
PASI: Psoriasis Area and Severity Index
Key safety 
assessmentsAdverse events and serious adverse events
Laboratory assessments (e.g., hematology, clinical chemistry , hs-CRP, HbA1c, 
HOMA -IR, viral serology, serum and urine pregnancy )
Vital signs, weight, waist circumference, BMI, physical examination
Data analysisA designated Contract Research Organization will perform the statistical analy sis.
It is planned that the data from all centers that participate in this protocol will be 
combined, so that an adequate number of patient s will be available for analy sis.
The analysis will be conducted on all patient data at the end of W eek 12, and at the 
time the trial ends at Week 53.
The following analysis sets will be used for the statistical reporting and analy ses:
Randomized Set: The Randomized Set includes all randomized patient s.  
Safety Set: The Safety Set includes all patient s who received at least one dose of 
study medication.  Patient s will be included in the analy sis according to treatment 
received.
Full Analysis Set:  The Full Analysis Set comprises all patient s to whom study 
medication has been assigned .  Patient s inappropriately randomized (e.g., IRT was 
called in error for randomization of a screen failed patient ) will be excluded from this 
analysis set.
Data will be summarized by stratumwith respect to demographic and baseline 
characteristics of all patient s for the Randomized Set and the Full Analy sis Set.
Concomitant medications will be summarized by treatment using frequency counts 
and percentages for the Safety  Set.
Efficacy , safety, and other data will be summarized for all weeks up to Week 53.
Response of psoriasis skin lesions to treatment as measured by :
a. Response inskinhistology/K16 expression to treatment  (yes, no)
b. PASI 90 (yes, no)
The primary  analysis time point will be at W eek 12.
For the two primary efficacy variables at each time point (response inskin 
histology/K16 expression to treatment at Week 12, PASI 90 at Weeks 4, 8, and 12), 
95% confidence intervals for the difference between the two treatment groups with 

Novartis Confidential Page 14
Amended Protocol Version 02 (Clean) Protocol No. CAIN457AUS07
respect to the percentage of patient s who have the “event” willbe calculated using 
the normal approximation to the binomial distribution.
For the two primary  efficacy variables at Week 12 (and other time points), a patient
with a missing assessment will be considered as a non -responder.
The analysis of the primary ef ficacy  variables will be based on the Full Analy sis Set.
Cross -classification tables of response in skin histology/K16 expression to treatment 
(yes, no)  
 
  In addition, to assess the association 
between skin histology/K16 expression results , a logistic regression 
analysis will be performed and the odds ratio and 95% confidence interval for the 
odds ratio based on the fitted model will be reported.  The model will include 
response in skin histology/K16 expression as the response variable and treatment, 
body  weight (<90 kg, ≥90 kg), .  
 
The assessment of safety will be based mainly on the frequency of adverse events 
and laborator y data.  Other safety data, including vital signs (weight, blood pressure, 
waist circumference, BMI), and clinical laborator y variables (glucose, insulin, hs-
CRP, HOMA -IR, HbA1c) will be summarized by strat um, as appropriate.
Analysis of safety data will be based on the Safety Set.
The table below considers total sample sizes of 75 patient s (50 in secukinumab 
group and 25 in placebo group) and 99 patient s (66 in secukinumab group and 33 in 
placebo group) to estimate the difference between the two groups with respect to the 
pooled estimate of the two percentages of patient s who have the “event” at W eek 12 
for each of the two primary efficacy variables.  The entries in the table are the 
“margin of error” (half-width of confidence interval) for a two-sided 95% confidence 
interval (Julious and Patterson, 2004 ; Kianifard and Islam , 2011; nQuery Advisor 
7.0).
Percentage with 
“event”Half-width of 
confidence interval for 
n = 75Half-width of 
confidence interval 
for n = 99
30% 25.0% 21.4%
40% 26.5% 22.7%
50% 27.0% 23.2%
60% 26.5% 22.7%
70% 25.0% 21.4%
Based on the results in the above table, it was decided that approximately 75 
randomized patient s (50 in secukinumab group and 25 in placebo group) will be 
randomized inthis  study to estimate the difference in response rates 
between the two treatment groups .
Key wordsPlaque psoriasis, secukinumab, biologic, monoclonal antibody, adipose tissue, skin 
inflammation

Novartis Confidential Page 15
Amended Protocol Version 02 (Clean) Protocol No. CAIN457AUS07
1 Introduction
1.1 Background
Psoriasis vulgaris is best conceptualized as a disease of focal cutaneous inflammation, but 
with associated systemic inflammation that likel y results from effects of circulating cytokines 
and other inflammatory molecules that are produced at excess levels in skin lesions and 
diffuse into the circulation.  IL-17 and tumor necrosis factor (TNF )are consistently  increased 
in plasma of untreated patients with moderate -to-severe psoriasis and these are decreased 
following skin improvements with a number of biolo gic treatments, e.g., IL-23 inhibitors or 
TNF inhibitors ( Chiricozzi et al 2011).
Consequences of cytokine -driven system inflammation include: 1) activation of a set of genes 
and proteins in circulating leukocy tes that increase inflammatory  potential and would enable 
migration into various tissues according to chemokine gradients that may be set up; 2) 
vascular inflammation associated with large vessels as demonstrated by PET-CT imaging in 
past studies; 3) an increase in cardiovascular disease (CVD) risk; 4) inflammation in adipose 
tissue with the consequence of increased resistance to insulin signaling and metabolic 
syndrome or diabetes; and 5) inflammation in other tissues such as the gut or joints that may 
drive increased incidence of inflammatory  bowel disease or psoriatic arthritis, respectivel y 
(Davidovici et al 2010 ).
Psoriasis is also associated with overt obesity  in a large fraction of patients.  While IL-17 is 
not established as a factor in the formation of excess adiposit y, there are reports that suggest 
obesity  may be a driver for the formation of Th17 T-cells (Endo et al 2015 ; Luczyński et al 
2015; Reis et al 2015 ).  Additionally , treatment of patients with TNF antagonists can lead to 
significant weight gain, a finding that worsens the obesity  problem and which mechanistically 
makes sense with inh ibition of TNF signaling ( Tan et al 2013 ; Renzo et al 2011 ; Gisondi et al 
2008; Saraceno et al 2008 ).
Therapeutic agents with different mechanisms, e.g., secukinumab, would not be expected to 
produce this negative effect of weight gain. The metabolic and inflammatory  effects of IL-17 
signaling in adipose tissue are not well understood at present, but use of a directed IL-17 
antagonist has the potential to define the phy siological effects of excess IL -17 signaling in this 
tissue compartment. Thus this study  has the potential to establish non -negative effects (i.e.
, no 
weight gain) of secukinumab on adiposity , as well as pro -health consequences of blocking IL-
17 in psoriasis patients.
The present study  has the dual goals of examining anti-inflammatory  effects of secukinumab 
on two “systemic” tissues that lead to co-morbidity :  the vascular compartmen t and 
subcutaneous adipose tissue.  In both cases, treatment benefits would be related to reductions 
in inflammation in psoriasis vulgaris skin lesions.  Elements of the vascular compartment that 
affect cardiovascular disease that will be studied include e ndothelial cells (via microparticles), 
circulating leukocy tes (via microparticle and full cell analysis), and 
inflammatory /cardiovascular risk proteins in blood plasma (Ho et al 2016 ).  Elements of the 
adipose tissue response include the study  of overall adiposity  (e.g., weight, BMI).

Novartis Confidential Page 16
Amended Protocol Version 02 (Clean) Protocol No. CAIN457AUS07
Ongoing studies are using PET-CT or PET-MRI to visualize inflammation in large vessels 
during secukinumab treatment, but this imaging is based on metabolic activity  of 
macrophages that are resident within the sub-endothelial space of large vessels and 
macrophage infiltration of any tissue may be relatively  fixed and non -reversible, even with 
strong anti-inflammatory treatments (Mehta et al 2011; Naik et al 2015 ).  Researchers at 
 have found that aortic endothelial cells respond to the combination of 
TNF and IL-17 by synthesis of fractalkine, which is a chemotactic chemokine for 
“inflammatory ’ macrophages that are associated with atherosclerosis formation.  
Macrophages with this phenoty pe have been identified in blood of psoriasis patients.  The 
effects of high levels of IL-17, TNF, and leukocyte trafficking across aortic endothelium will 
set-up increased microparticles (apoptotic bodies) derived from these endothelial cells in the 
blood.  A beneficial effect of IL-17 blockade on aortic inflammation can thus be measured by 
quantification of endothelial cell derived microparticles as well as expression of cytokine -
induced proteins, e.g., adhesion molecules such as ICAM-1 and VCAM, in these particles 
using flow -cytometry  with appropriate antibodies to quantify  levels of protein expression.
In a recent study  of IL-17 inhibition with ixeki zumab, researche rs at  
were able to demonstrate that a set of IL-17 induced adhesion molecules on blood monocy tes 
were reduced at the level of gene expression within two weeks of starting this antibody  (Wang 
et 
al 2014 ).  The current proposal would extend this analy sis to include measuring expression 
of cognate surface proteins on circulating leukocy tes, including inflammatory  macrophages, 
and the integration of this data with expression of cy tokine-induced proteins on microparticles 
derived from endothelial cells and leukocy tes.
Finally , a recent study  has found that there was increased expression of IL-17 signaling
pathway s in non -lesional skin of psoriasis patients ( Chiricozzi et al 2016 ).  As a feature of this 
protocol , we would correlate anti-inflammatory  effects of secukinumab in “internal” sites of 
endothelium, blood leukocytes,  after treatment to 
test this hypothesis.  If the concept is validated, it could have tremendous benefit for the 
design of future studies designed to prove “distant” effects of inflammatory  cytokines in 
psoriasis patients on peripheral tissues.
1.2 Purpose 
Obesity  has been linked to poorer long-term outcome in patients with psoriasis, with some 
evidence that weight loss may improve psoriasis 
(Higa- Sansone et al 2004 ; Naldi et al 2005; 
Wolters 2005).  In addition, one recent study  showed that moderate weight loss may 
supplement pharmacologic treatment (Giscondi et al 2008).  However, what isunclear is if 
inflammatory  cytokines upregulated in psoriasis 
patients by the TH-17 pathway  are also 
contributing to the production of adipose tissue in these patients, and thereb y also affecting 
the mechanism of insulin resistance.  These factors may contribute to the higher association of 
complications from insulin resistance such as dy slipidemia, hy pertension, and premature heart 
disease in psoriasis patients.  Patients with moderate to severe psoriasis who undergo anti-IL-
17A treatment with secukinumab that improves the skin manifestations of psoriasis but its 
effect on adipose tissue are also of intense clinical and scientific interest.

Novartis Confidential Page 17
Amended Protocol Version 02 (Clean) Protocol No. CAIN457AUS07
The purpose of this study  is to explore changes in subcutaneous adipose tissue and skin 
inflammation in patients with moderate to severe plaque psoriasis treated with secukinumab 
300 mg compared to placebo at Week 12.
2 Study  objectives and endpoints
2.1 Objectives and related endpoints
Table 2-1 Objectives and related endpoints
Objective(s) Endpoint(s)
Primary Objective(s)
To explore the modulation of 
subcutaneous adipose tissue and skin 
inflammation from baseline to Week 12 
in patient s with moderate to severe 
plaque psoriasis treated with 
secukinumab compared to placeboEndpoint(s ) for primary objective(s)
Response of psoriasis skin lesions to 
treatment as measured b y:
a.Response in skin histology /K16 
expression to treatment (yes, no)
b.PASI  90(yes, no)
Secondary Objective(s)
To explore changes in biometric 
measurements from baseline to Week 12 
in patients with moderate to severe 
plaque psoriasis treated with 
secukinumab compared to placeboEndpoint(s) for secondary objective(s)
Vital signs (blood pressure, weight, 
waist circumference, BMI), clinical 
laboratory  variables (gluc ose, insulin, 
hs-CRP, HOMA -IR, HbA1c)
To explore the modulation of 
subcutaneous adipose tissue and skin 
inflammation from baseline to Week 52 
in patien
ts with moderate to severe 
plaque psoriasis treated with 
secukinumabResponse of psoriasis skin lesions to 
treatment as measured b y:
a.Response in skin histology /K16 
expression to treatment (yes, no)
b.PASI  90(yes, no)

Novartis Confidential Page 18
Amended Protocol Version 02 (Clean) Protocol No. CAIN457AUS07
3 Investigational plan
3.1 Stud y design
This study  uses a randomized, double -blind, placebo- controlled, parallel- group, multicenter 
design.  Approximately  75 moderate to severe plaque psoriasis patients from approximately  
15 sites will be randomized at Visit 2/Baseline in a 2:1 ratio to receive secukinumab 300 mg 
or placebo, respectivel y.  Randomization will be stratified by  body  weight collected at Visit 2 
(< 90 kg or ≥ 90 kg).
The study  consists of f iveperiods:
Screening (from 1- 4 weeks);
Double-blind Treatment Period (12 weeks);
Double- blind I nduction Period (4 weeks); 
Open -label Treatment Period (36 weeks) ; and
Follow -up Period (1 week) .
A schematic of the study  design is presented in Figure 3-1, while a detailed visit and 
assessment schedul e can be found in Table 6-1.  An interim analy sis is planned after Week 
12,which is the primary  anal ysis time point for the study .

Novartis Confidential Page 19
Amended Protocol Version 02 (Clean) Protocol No. CAIN457AUS07
Figure 3 -1 Study  design
3.1.1 Screening period (Screening to randomization)
The duration of the screening period will be up to four weeks.  Screening will be used to 
assess patient eligibility  and to taper patien
ts off prohibited medications and treatments.
3.1.2 Double -blind treatment period (Randomization to Week 12 pre -dose)
Atthestart ofthe Double- blind Treatment Period, eligible patients will berandomi zed 
via Interactive Response Technology  (IRT) in a 2 :1ratio to one of two tr eatment arms
(secukinumab 300 m g or placebo).  Randomization will be stratified by body weight collected 
at Visit 2 (< 90 kg or ≥90 kg).
Duringthis period ,all patien tswillattend study  visits atBaseline, Weeks 1, 2, 3, 4, 8 and12, 
and all doses of stud y treatment will be self- administered at the study  site.
 
Assessments fortheprima ryefficacy  variable willbeperformed atWeek12 pr iorto patients 
receiving their Week12 dose.
Allpatien tswho discontinue from the studyprematurely for any re asonbefore theendof
the Double -blind Treatment Period should return to the study  site for the performance of the 
Visit 8/Week12End ofTreatment (EOT1) assessments. Thisvisit should be scheduled 
appro ximate lyfour weeks afterthelastdose ofstudy treatment.

Novartis Confidential Page 20
Amended Protocol Version 02 (Clean) Protocol No. CAIN457AUS07
3.1.3 Double -blind induction period (Week 12 dose through Week 15 dose)
All patient s who complete the Double- blind Treatment Period will enter the Double- blind 
Induction Period.  The Double -blind Induction Period is defined as the Week 12 dose through 
the Week 15 dose.
During this period, patien ts randomized to receive placebo at Visit 2/Baseline will be 
switched over to treatment with secukinumab 300 mg weekly  for four weeks at Weeks 12, 13, 
14, and 15.
Patients who were randomized to the secukinumab treatment group at Visit 2/Baseline will 
continue to self-administer secukinumab 300 mg at the Week 12visit. In order to maintain 
the blind for the 12-week, placebo -controlled period, these patients will self-administer 
placebo injections at Weeks 13, 14 ,and 15.
Self-administration of the Week
s 12 and 13 doseswill take place at the study  site, while the 
doses at Weeks 14 and 15 will be self- administered at home.
All patient s who discontinue from the study  prematurely  for any reason before the end of 
Double- blind Induction Period should return to the study  sitefor the performance of the Visit 
15/Week 52 End of Treatment (EOT2) assessments.  This visit should be scheduled 
approximately  four weeks after the last dose of study  treatment.
3.1.4 Open -label treatment period (Week 16 to Week 52)
All patient s who complete the Double -blind Induction Period will enter the Open -label 
Treatment Period.  The Open- label Treatment Period is defined as Week 16 through Week 52. 
All patients in this period will receive secukinumab 300 mg s.c. at four-week intervals 
beginning at Week 1 6 through Week 48 (last dose during the Open -Label Treatment Period).
Self-administration of the doses at Weeks 16, 24, 32, 40, and 48 will take place at the study 
site; the doses at Weeks 20, 28, 36, and 44 will be self -administered at home.
All patients who discontinue from the study  prematurel y for any reason before the end of the 
Open -label Treatment Period should return to the study  site for the performance of the Visit 
15/Week 52 ( EOT2 )assessm ents. Thisvisit should be scheduled approximately  four weeks 
after the last dose of study  treatment. 
3.1.5 Follow -up period visit 1 (F1)
All patients who undergo skin biopsies at Visit 15/Week 52will return to the site 
approximately seven days later for Follow -up V isit 1(F1) for suture removal and safet y check.
Additionally , all patients who discontinue prematurely  from the study  and who undergo skin 
biopsies at their end of treatment visit (either Visit 8/Week 12 EOT1 or Visit 15/Week 52 
EOT2) will retur n to the site approximately  seven days later for Follow -up Visit 1 (F1) for 
suture removal and safety check.

Novartis Confidential Page 21
Amended Protocol Version 02 (Clean) Protocol No. CAIN457AUS07
3.1.6 Control cohort of healthy volunteers sub-study
Health y volunteers will be enrolled at a single site( )to act as a 
control cohort for the purpose of comparing skin, adipose tissue,  
data/outcomes to the psoriasis patients enrolled in the study .  Approximately  20 subjects
without plaque psoriasis will be enrolled into the control cohort .  These healthy  volunteers 
will not receive stud y treatment.
Once all psoriasis patien ts have 
been randomized into the study , a listing of the requisite 
demographic and baseline characteristics (age, gender, weight, BMI) for the psoriasis study 
patients will be generated by Novartis from the clinical database and provided to The 
 through an appropriate secure channel.  This data is necessary  for 
matched healthy  volunteers to be recruited into the control cohort. 
The control cohort will be enrolled while the 52-week treatment period for the psoriasis 
patien
ts is ongoing; it is planned that the sample from the last healthy volunteer will be 
collected b y the time the last psoriasis subject completes Week 52/EOT visit.   
After signing informed consent, subjects in the control cohort will complete the assessments
(including safet y assessments) as indicated in Table 6-2.  Visit 1 assessments may or may not 
occur on the same day .
During Visit 1, demograp hic and baseline characteristic data will be collected.   
 
   
 Subjects will return to the site approximately  7 
days following the Visit 1 biopsy  for suture removal and safety  check.
The analyses for the control cohort will be done in parallel with the psoriasis study  patients, 
such that when the Week 52 data from the psoriasis patients is analy zed, the control data from 
the health y volunteers will be available for comparison.
The control data and the psoriasis baseline and treatment data are 
best analy zed in a single 
batch and with a statistical model (a mixed effects model) that will consider group (control vs. 
disease), as well as treatment effects. The control data are needed to establish which baseline 
values of skin, fat, or blood measures are abnormal as a function of disease at baseline. This 
then 
provides the ability to determine if treatment with secukinumab normalizes baseline 
values or has effects to change inflammation that go beyond baseline disease 
characteristics. Without the control group, only a “drug effect” on the disease parameters 
could be computed without knowing whether what is modulated is part of pathogenic 
inflammation.
Inclusion criteria
Subjects in the control cohort will be judged by the investigator to be generall y healthy ,and 
will be generall y matched to the age, gender, race, and weight/BMI composition of 
thepsoriasis study  patients.   

Novartis Confidential Page 22
Amended Protocol Version 02 (Clean) Protocol No. CAIN457AUS07
Exclusion criteria
Subjects fulfilling any  of the following criteria are not eligible to enroll into the control cohort:
Current use of im munosuppressive medications;
Current use of anti -coagulant medications;
Use of any investigational treatment within 4 weeks prior to study  enrollment, or 
within a period of 5 half-lives of the investigational treatment prior to study 
enrollment, whichever is longer ;
Having a known autoimmune or inflammatory  disease;
History  or evidence of ongoing alcohol or drug abuse, within the last 6 months prior 
to randomization;
Pregnant or nursing (lactating) women.
3.2 Rationale for study  design
The randomized, double -blind, placebo -controlled design used in this study is aligned with the 
Phase III trials of secukinumab, and with previous studies performed in the indication of 
chronic plaque psoriasis, and is in accordance with health authority  guidelines and feedback, 
including the United States Food and Drug Administration (FDA).
The study  population consists of adult patients with moderate to severe plaque -type psoriasis 
who are candidates for s ystemic therap y or phototherap y.
The primary  analysis time point of the trial is at Week 12.  This is in line with the timing of 
the primary  analysis time point in the secukinumab Phase III trials, and will allow for 
assessment of efficacy  at a point in time for which efficacy  data from currentl y approved 
biologic therapies are available.  Additionally , it is unknown if modulation of adipose tissue 
by secukinumab will be detectable by the primary  time point of 12 weeks.  The study  design 
provides for treatment a duration of 52 weeks, which willallow for the assessment of longer -
term effects of secukinumab in adipose tissue .  For patients randomized to receive placebo at 
Visit 2/Baseline, the 52-week treatment duration allows these patients the opportunity  to 
receive up to 40 weeks of treatment with secukinumab.
The study  population will be described in more detail in Section 4 below.
3.3 Rationale for dose/regimen, route of administration and duration 
of treatment
The proposal to use a dose of secukinumab 300 mg administered with a weekl y induction 
regimen for five weeks (at Randomization, Weeks 1, 
2, 3, and 4) followed by treatment every 
four weeks thereafter (starting at Week 8) is in accordance with the current FDA -approved 
product labeling.
3.4 Rationale for choice of comparator
Due to the nature of psoriasis and the outcome measures used for this indication, a placebo 
arm is necessary  to obtain reliable efficacy  measurements.  Moreover, the inclusion of a 

Novartis Confidential Page 23
Amended Protocol Version 02 (Clean) Protocol No. CAIN457AUS07
placebo group is in accordance with health authority  guidelines and feedb ack (CHMP 
Psoriasis Guideline -CHMP/EWP/2454/02 2004).  The continuation of the placebo group up to 
the primary  analysis time point at Week 12 is in the study  design for the indication of chronic 
plaque -type psoriasi s and is accepted by health authorities including the FDA, EMA and 
PMDA.
3.5 Purpose and timing of interim analy ses/design adaptations
The primary  anal ysis at Week 12 is considered an interim analysis and will be performed after 
all patients have completed theWeek 12 visit and the database is locked.  As Week 12 is the 
primary  analysis time point, no adjustment to the significance level of 0.05 will be made.  See 
Section 5.4 on treatment blinding for additional i nformation.
For the purpose of developing a potential sub -study , the summary  of patient demographic and 
baseline characteristics may  be used.
3.6 Risks and benefits
Secukinumab is currently approved in the United States for the treatment of moderate to 
severe plaque psoriasis in adult patients who are candidates for systemic therap y or 
phototherap y.
The potential benefits of secukinumab treatment are detailed in Section 3.6.1 .
The risk to patients in this trial will be minimized by compliance with the eligibility  criteria 
and close clinical monitoring.
  Specifical ly, there is the risk of infection, 
bleeding and potentially  unsatisfactory  cosmetic results, e.g., due to scarring.  A skin scar is 
expected after each biopsy procedure.
All quality , non- clinical pharmacology  and toxicology  data, as well as the available clinical 
efficacy  and safet y data for secukinumab are considered sufficient to expect a positive 
benefit/risk ratio for the treatment of moderate to severe psoriasis with secukinumab.
The Investigator’s Brochure (IB) provides a more detailed review of the pre-clinical and 
clinical information on secukinumab.
3.6.1 Clinical trials experience in plaque psoriasis
Four multicenter, randomized, double -blind, placebo -controlled trials (Trials 1, 2, 3, and 4) 
enrolled 2403 subjects (691 randomized to secukinumab 300 mg, 692 to secukinumab 150 mg, 
694 to placebo, and 323 to a biologic active control) 18 years of age and older with plaque 
psoriasis who had a minimum body  surface area involvement of 10%, and Psoriasis Area and 
Severity  Index (PASI) score greater than or equal to 12, an Investigator Global Assessment 
modified 2011 (IGA) of at least 3, and who were candidates for phototherap y or systemic 
therap y.
Trial 1 enrolled 738 subjects (245 randomized to secukinumab 300 mg, 245 to 
secukinumab 150 mg, and 248 to placebo).  Subjects received subcutaneous treatment at 
Weeks 0, 1, 2, 3, and 4 followed by dosing every  4  w eeks.  Subjects randomized to 

Novartis Confidential Page 24
Amended Protocol Version 02 (Clean) Protocol No. CAIN457AUS07
secukinumab received 300 mg or 150 mg doses at Weeks 0, 1, 2, 3, and 4 followed by  the 
same dose every  4  w eeks.  Subjects rando mized to receive placebo that were non-
responders at Week 12 were then crossed over to receive secukinumab (either 
300 mg or 
150 mg) at Weeks 12, 13, 14, 15, and 16 followed by the same dose every  4 weeks.  All 
subjects were followed for up to 52 weeks following first administration of study 
treatment.
Trial 2 enrolled 1306 subjects (327 randomized to secukinumab 300 mg, 327 to 
secukinumab 150 mg, 326 to placebo and 323 to a biologic active control).  Secukinumab 
and placebo data are described.  Subjects received subcutaneous treatment at Weeks 0, 1, 
2, 3, and 4 followed by dosing every  4 weeks.  Subjects randomized to secukinumab 
received 300 mg or 150 mg doses at Weeks 0, 1, 2, 3, and 4 followed by the same dose 
every  4 weeks.  Subjects randomized to recei ve placebo that were non -responders at Week 
12 then crossed over to receive secukinumab (either 300 mg or 150 mg) at Weeks 12, 13, 
14, 15, and 16 followed by the same dose every  4 weeks.  All subjects were followed for 
up to 52 weeks following first admini stration of study  treatment.
Trial 3 enrolled 177 subjects (59 randomized to secukinumab 300 mg, 59 to secukinumab 
150 mg, and 59 to placebo) and assessed safet y, tolerability , and usability  of secukinumab 
self-administration via prefilled syringe for 12 w eeks. Subjects received subcutaneous 
treatment at Weeks 0, 1, 2, 3, and 4, followed by  the same dose every  4 weeks for up to 12 
weeks total.
Trial 4 enrolled 182 subjects (60 randomized to secukinumab 300 mg, 61 to secukinumab 
150 mg, and 61 to placebo) a nd assessed safet y, tolerability , and usability  of secukinumab 
self-administration via Sensoread y pen for 12 weeks. Subjects received subcutaneous 
treatment at Weeks 0, 1, 2, 3, and 4, followed by  the same dose every  4 weeks for up to 12 
weeks total.
In all trials, the co-primary  efficacy  variables were the proportion of subjects who achieved a 
reduction in PASI  score of at least 75% (PASI  75) from baseline to Week 12 and treatment 
success (clear or almost clear) on the Investigator’s Global Assessment modified 2011 (IGA 
mod 2011). Other evaluated outcomes included the proportion of subjects who achieved a 
reduction in PASI score of at least 90% (PASI 90) from baseline at Week 12, maintenance of 
efficacy  to Week 52, and improvements in itching, pain and scaling at Week 12 based on the 
Psoriasis Sy mptom Diary©.
The PASI  is a composite score that takes into consideration both the percentage of body 
surface area affected and the nature and severity  of psoriatic changes within the affected 
regions (induration, erythema and scaling). The IGA mod 2011 is a 5-category  scale 
including “0 = clear” “1 = almost clear”, “2 = mild”, “3 = moderate” or “4 = severe” 
indicating the physician’s overall assessment of the psoriasis severity  focusing on induration, 
erythema and scaling. Treatment success of “clear” or “almost clear” consisted of no signs of 
psoriasis or normal to pink coloration of lesions, no thickening of the plaque and none to 
minimal focal scaling.
The results of Trials 1 -
4are presented in Table 3 -1.

Novartis Confidential Page 25
Amended Protocol Version 02 (Clean) Protocol No. CAIN457AUS07
Table 3-1 Clinical outcomes at Week 12 in adults with plaque psoriasis in Trials 
1- 4
Trial 1 Trial 2 Trial 3 Trial 4
Secukinumab
300 mg
(N=245)
n (%)Placebo
(N=248)
n (%)Secukinumab
300 mg
(N=327)
n (%)Placebo
(N=326)
n (%)Secukinumab
300 mg
(N=59)
n (%)Placebo
(N=59)
n (%)Secukinumab
300 mg
(N=60)
n (%)Placebo
(N=61)
n (%)
PASI 90 
response145 (59) 3 (1) 175 (54) 5 (2) 35 (60) 0 (0) 33 (55) 0 (0)
IGA of 
clear or 
almost 
clear160 (65) 6 (2) 202 (62) 9 (3) 40 (68) 0 (0) 44 (73) 0 (0)
Examination of age, gender, and race subgroups did not identify  differences in response to 
secukinumab among these subgroups.  
PASI  90 response at Week 12 was achieved with secukinumab 300 mg and 150 mg compared 
to placebo in 59% (145/245) and 39% (95/245) versus 1% (3/248) of subjects, respectivel y 
(Trial 1) and 54% (175/327) and 42% (137/327) versus 2% (5/326) of subjects, respectivel y 
(Trial 2).  Similar results were seen in Trials 3 and 4.
With continued treatment over 52 weeks, subjects in Trial 1 who were PASI  75 responders at 
Week 12 maintained their responses in 81% (161/200) of the subjects treated with 
secukinumab 300 mg.  Trial 1 subjects who were clear or almost clear on the IGA at Week 12 
also maintained their responses in 74% (119/160) of subjects treated with secukinumab 300 
mg.  Similarly  in Trial 2, PASI  75 responders maintained their responses in 84% (210/249) of 
subjects treated with secukinumab 300 mg.  Trial 2 subjects who were clear or almost clear on 
the IGA also maintained their responses in 80% (161/202) of subjects treated with 
secukinumab 300 mg.
Among the subjects who chose to participate (39%) in assessments of patient reported 
outcomes, improvements in signs and symptoms related to itching, pain, and scaling, at Week 
12 compared to placebo (Trials 1 and 2) were observed using the Psoriasis Sy mptom Diary©.
3.6.2 Infections
Secukinumab may increase t
heriskof in fections.  In clinical trials, a higherr at e of infections
wasobserv ed i n secukinumab -treated subjects c ompared to pla cebo -treated subject s. I n 
placeb o -controlled clinical trials in pati ents with moderate to sever e plaque pso riasis, hig her
ratesof common inf ec tions suchasnasopharyngitis (11.4% versu s 8.6%), upper r esp iratory
t
ractinfec tion (2.5% versu s 0.7%) and m ucocu tane ous inf ections with Candida ( 1.2% versus
0.3%) wer e observedwit h secukinumab compar edwith p lacebo.  A sim ilarincrea sei n ri skof
infection wa s seenin pl acebo-controlled trials in pa tie n ts with pso riatic arthritis and 
anky l osi ngspond ylitis .  The inciden ce of so me typesof in fections appeared to bedose-
dependent in clinical studi es. Proper exclusion criteria will be applied in this study  to ensure 
subject safet y.

Novartis Confidential Page 26
Amended Protocol Version 02 (Clean) Protocol No. CAIN457AUS07
3.6.3 Pre-treatment evaluation for tuberculosis
Evaluate subjects for tuberculosis (TB) infection prior to initiating tr ea tment with
secukinumab.   Do not administ er secukinumab t o subjects with ac tive TB infection.  Ini tiate
treatmentof lat entTB p rior to administe ringsecukinumab .  C onsid eranti-TB ther apy prior to
initia tion ofsecukinumab in patient s witha pasthisto ry of latent oractiveTBin whom an 
adequat e cours e of treatm entcannot be confirmed.  Pat i ents receivi ngsecukinumab should b e 
monitor edc lo sely fo r signs and sympto ms ofactiv e TB duri ngand a ft ertreatm ent.
3.6.4 Inflammatory  bowel disease
Caution should be used when presc rib i ngsecukinumab to pa tie n ts with infla mmatory bowel
disease. Exacerba t ions, in some casess erious, occurred in secukinumab -tre ated patien ts 
duringc linical trials in pl aque ps o riasis,psoria tic arthriti s and ankylosing spond ylitis. In 
addition, new onset inflammatory bow eldiseas e cases o ccurredin clini caltria ls w ith 
secukinumab .  In an exp lora t ory stu dyin 59 patient s w ith ac tive Crohn’ s disease, ther e were
trends toward greater disea se act iv ityand increased adverseevents in t he secukinumab group 
as co mpar edto th e placebo g ro up.  Patients who ar e treated with secukinumab should b e 
m
onitor edf or sig ns andsymptoms ofinflammatory bow eldisease.
3.6.5 Hypersensitivity  reactions
Anaph ylaxis and cases of urticaria occurred in secukinumab -treated subjects in the clinical 
trials.  If an anaphy lactic or other serious allergic reaction occurs, administration of 
secukinumab should be discontinued immediately  and appropriate therapy  initiated.
3.6.6 Risk of hy persensitivity  in latex -sensitive Individuals
The removable cap of the secukinumab prefilled syringe contains natural rubber latex which 
may cause an allergic reaction in latex -sensitive individuals.  The safe use of the secukinumab 
prefilled s yringe in latex -sensitive individuals has not been studied.
3.6.7 Vaccinations
Prior to initiating therapy  with secukinumab, consider completion of all age appropriate 
immunizations according to current immunization guidelines.  Subjects treated with 
secukinumab should not receive live vaccines.  Non-live vaccinations received during a 
course of secukinumab may  not elicit an immune response sufficient to prevent disease.
4 Population
The study  population will consist of male and female patien
ts (≥18 years of age) with 
moderate to severe chronic plaque -type psoriasis that requires systemic therap y, which is 
defined as psoriasis that is inadequat ely controlled by topical treatments (including topical 
corticosteroids (TCS)), ultraviolet (UV) light, or sy stemic therapy .
The goal is to randomize a total of 75 patien ts in approximately  12centers in the United 
States.  Since a 30% screen failure rate is expected, approximately  107 patien ts will be 
screened.

Novartis Confidential Page 27
Amended Protocol Version 02 (Clean) Protocol No. CAIN457AUS07
Patien ts who discontinue after they have been randomized will not be replaced.
4.1 Inclusion criteria
Patients eligible for inclusion in this study  must fulfill all of the following criteria:
1.Written in formed consent must be obtained before any assessment is performed
2.Males and females 
≥18 years of age at the time of screening
3.Clinical diagnosis of chronic plaque -type psoriasis at least 6 months prior to 
randomization as determined by patien t interview of his/her medical history  and by 
confirmation of diagnosis through ph ysical examination by  the investigator
4.Moderate to severe plaque psoriasis as defined at baseline by :
≥10% Bod y Surface Area (BSA) involvement and
PASI  total score of ≥12 and
IGA mod 2011 score of ≥3 (based on a scale of 0 -4)
5.Candidate for s ystemic therapy , defined as having psoriasis inadequatel y controlled by :
Topical treatment (including topical corticosteroids) and/or
Phototherapy  and/or
Previous sy stemic therapy
4.2 Exclusion criteria
Patients fulfilling any of the following criteria are not eligible for inclusion in this study . No 
additional exclusions may be applied by the investigator, in order to ensure that the study 
population will be representative of all eligible patients.
1. Forms of diagnosed psoriasis other than chronic plaque psoriasis (e.g., erythrodermic, 
generalized or localized pustular psoriasis, or new onset guttate psoriasis)
2. Medication -induced or medication exacerbated psoriasis (e.g., new onset or current 
exacerbation from beta -blockers, calcium channel inhibitors or lithium)
3.
Previous exposure to secukinumab or any other biologic drug directl y targeting IL-17A 
or IL -17RA receptors (e.g., ixekizumab, or brodalumab)
4. Diagnosis of other active ongoing skin disease s or skin infections (bacterial, fungal, or 
viral), or inflammatory diseases other than psoriasis that may interfere with the 
evaluation of psoriasis
5. Ongoing use of treatments prohibited by  the protocol (see Section 5.5.8 , Table 5 -1)
6. Plans for administration of live vaccines during the study  period or within 6 weeks 
before randomization
7. Use of any investigational treatment within 4 weeks prior to Randomization, or within a 
period of 5 half-lives of the 
investigational treatment prior to Randomization, whichever 
is longer

Novartis Confidential Page 28
Amended Protocol Version 02 (Clean) Protocol No. CAIN457AUS07
8. Currently  enrolled in any other clinical trial involving an y investigational agent or device
9. Patients using cholesterol -lowering medication (e.g., statins) who have not been on a 
stable dose for at least 90 day s prior to randomization and who are unable to remain on a 
stable dose for the duration of the study
10. Pregnant or nursing (lactating) women
11. Women of child- bearing potential, defined as all women physiologically  capable of 
becoming pregnant, unless they are using effective methods of contraception during 
dosing of study  treatment and for 16 weeks after stopping of study  treatment.  Basic 
contraception methods include:
Total abstinence (when this is in line with the preferred and usual lifest yle of the 
patient. Periodic abstinence (e.g., calendar, ovulation, sy mptothermal, post- ovulation 
methods) and withdrawal are not acceptable methods of contraception
Female steriliza tion (have had surgical bilateral oophorectom y with or without 
hysterectom y), total h ysterectom y or tubal ligation at least six weeks before taking 
study  treatment. In case of oophorectom y alone, only  when the reproductive status of 
the woman has been conf irmed by  follow up hormone level assessment
Male sterilization (at least 6 months prior to screening). For female patients on the 
study , the vasectomized male partner should be the sole partner for that patien t
Barrier methods of contraception: Condom or Occlusive cap (diaphragm or 
cervical/vault caps)
Use of oral, (estrogen and progesterone), injected or implanted hormonal methods of 
contraception or other forms of hormonal contraception that have comparable efficacy  
(failure rate <1%), for example hormon e vaginal ring or transdermal hormone 
contraception or placement of an intrauterine device (IUD) or intrauterine sy stem 
(IUS)
In cases of oral contraception use, women should have been stable on the same pill for 
a minimum of 3 months before taking stud y treatment.
NOTE : Women are considered post-menopausal and not of child bearing potential if they 
have had:
12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile 
(e.g. age appropriate, history  of vasomotor s ymptoms), or
surgical bilateral oophorectomy  (with or without hy sterectom y), total h ysterectomy  or 
tubal ligation at least six weeks ago.  In the case of oophorectom y alone, only  when 
the reproductive status of the woman has been confirmed by  follow up hormone level 
assessment is she considered not of child -bearing potential.
12. Current severe progressive or uncontrolled disease which in the judgment of the 
investigator renders the patien t unsuitable for the trial or puts the patient at increased risk
13. Any underl ying condition (including, but 
not limited to metabolic, hematologic, renal, 
hepatic, pulmonary , neurologic, endocrine, cardiac, infectious or gastrointestinal) which, 
in the opinion of the investigator, significantly  immunocompromises the patient and/or 
places the patient at unacceptable risk for receiving an immunomodulatory  therapy
14. Presence of significant medical problems, including but 
not limited to the following: 
uncontrolled hypertension with measured systolic >180 mmHg and/or diastolic >95 

Novartis Confidential Page 29
Amended Protocol Version 02 (Clean) Protocol No. CAIN457AUS07
mmHg; congestive heart failur e (New York Heart Association [NYHA] status of class III 
or IV
15. Fasting blood glucose ≥200 mg/dL and hemoglobin A1c ≥7% at screening; fasting 
glucose ≥150 mg/dL up to 199 mg/dL will require consultation with the Medical Monitor 
to confirm eligibility
16. Total white blood cell (WBC) count <2,500/μl, or thrombocy tes <100,000/μl, or 
neutrophils <1,500/μl, or hemoglobin <8.5 g/dL at screening
17. Active systemic infections during 2 weeks prior to randomization (exception: the 
common cold) or an y infection that reoccurs on a regular basis
18. History  of an ongoing, chronic or recurrent infectious disease, or evidence of 
tuberculosis infection as defined by a positive or indeterminate QuantiFERON TB-Gold 
test (QFT) at screening.
NOTE : Patient s with a positive QFT may  particip ate in the study  if a full tuberculosis 
work up (according to local practice/guidelines) completed within 12 weeks prior to 
randomization establishes conclusively  that the patien t has no evidence of active 
tuberculosis.  If the presence of latent tuberculo sis is established, then treatment must 
have been initiated and maintained for at least 4 weeks prior to randomization and the 
course of proph ylaxis is planned to be completed.
19. Positive serology  for human immunodeficiency  virus (HIV), hepatitis B or C infe ction at 
screening
20. History  of lymphoproliferative disease or any known malignancy  or history  of 
malignancy  of any  organ sy stem within the past 5 y ears (except for skin Bowen’s disease, 
squamous cell carcinoma, basal cell carcinoma, actinic keratoses that have been treated, 
carcinoma in situof the cervix, or non-invasive malignant colon polyps that have been 
removed)
21. History  or evidence of ongoing alcohol or drug abuse, within the last 6 months 
prior to 
randomization
22. History  of hypersensitivity  to constitue nts of the study  treatment and/or patien ts who are 
allergic to rubber or latex (the needle cap of the single -use prefilled syringe for 
secukinumab and placebo may contain natural rubber latex which may cause allergic 
reactions in latex sensitive individual s)
23. Any medical , psychiatric or other condition which, in the investigator’s opinion, would 
preclude the patien t from adhering to the protocol or completing the stud y per protocol
24. Patients who are not able and/or not willing to self -administer secukinumab injections or 
who have no trained caregiver available to administer these injections
5 Treatment
5.1 Stud y treatment
All
study treatments w illbesupplied by  Novartis and will be labeled appropriately.
All doses of study  treatment should be self-administered.  Self-administration ofthestudy
treatment referstopatient self-injection orinjection byatrained caregiver regardless of 

Novartis Confidential Page 30
Amended Protocol Version 02 (Clean) Protocol No. CAIN457AUS07
whether dosing occurs at the study  site or at home.  Instruction and training will be provided 
by site staff to patients /caregivers prior to self -injection.
Alldoses ofstudy treatment thatareadministered atthestudy siteshould beperformed after 
allstudy
assessments forthevisit have been completed.
5.1.1 Study drug – secukinumab
Secukinumab 150 mg: 1 ml liquid  formulation in a single -use prefilled s yringe (PFS)
Secukinumab for subcutaneous (s.c.) injection is provided in a PFS containing 150 mg 
secukinumab. Each secukinumab 300 mg dose is given as two s.c. injections of 150 mg.
5.1.2 Control drug –placebo
Placebo to secukinumab 150 mg: 1 ml liquid formulation in a single- use prefilled sy ringe 
(PFS)
Placebo to s ecukinumab 150 mg f or s.c. inj ection is provid edin a matching PFS. EachPFS
c
ontains a mixtur e of in active excipients, matching the composition of the se cukinumab 150
mg dos e. Each placebo dose is given as two s.c. injections of placebo to secukinumab 150 mg.
5.1.3 Additional treatment
No additional treatment bey ond the study drug and control drug are included in this trial.
5.2 Treatment 
groups
At Visit 2/Baseline, eligible patient s will be randomized to one of the following two treatment 
groups in a ratio of 2:1 :
Secukinumab group
Patients (or trained caregivers) will administer a dose of secukinumab 300 mg s.c. (two 
injections of the 150 mg PFS ) once weekl y for five weeks (at 
Baseline , Weeks 1, 2, 3, and 
4), followed b y dosing every  four weeks, starting at Week 8 through Week 48.  I n order to 
maintain the blinding for the 12 -week ,placebo -controlled period, two injections of the 
placebo PFS will be administered at Weeks 13, 14
,and 15 during the Double -blind 
Induction Period .
Placebo group
Patients (or trained caregivers) will administer a dose of placebo s.c. (two injections of the 
placebo PFS) once weekly  for five weeks (at Baseline , Weeks 1, 
2, 3, and 4), followed by 
a dose after four weeks at Week 8. 
Beginning at Visit 8/Week 12, all patien
ts in the placebo group will be switched to 
treatment with secukinumab 300 mg s.c.  Patients will receive a dose of secukinumab 300 
mg s.c. (two injections of the 150 mg PFS) once weekl y for five weeks (at Weeks 12, 13, 
14, 15, and 16) followed by  dosing every  four weeks starting at Week 20 through Week 
48.
The treatment groups and dosing frequency  are also described in Table 5 - 1below.

Novartis Confidential Page 31
Amended Protocol Version 02 (Clean) Protocol No. CAIN457AUS07
Table 5-1 Overview of study  treatment
Treatment group DB Treatment Period 
(Rand – Wk 12 pre -dose)DB Induction Period
(Wk 12 –Wk 15 )OL Treatment Period 
(Wk 16 –Wk 52)
Secukinumab 300 mg 
2x s.c. secukinumab 150 
mg injection at BSL, W ks 
1, 2, 3, 4 and 82x s.c. secukinumab 150 
mg injection at  Wk 12
2x s.c. PBO injection at 
Wks 13, 14 and 152x s.c. secukinumab 
150 mg injection at 
four-week intervals 
from Wks 16 -48
Placebo (PBO)
2x s.c. PBO injection at 
BSL, Wks 1, 2, 3, 4 and 82x s.c. secukinumab 150 
mg injection at Wks 12, 
13, 14, and 152x s.c. secukinumab 
150 mg injection at 
four-week intervals 
from Wks 16 –48
DB = Double -blind; OL = Open -label; PBO = placebo; BSL = Baseline; Wk = Week
5.3 Treatment assignment and randomization
At Visit 2/Baseline, all eligible patient s will be randomized via Interactive Response 
Technology  (IRT) to one of the two treatment groups. The investigator or his/her delegate 
will contact the I RT after confirming that the patient fulfills all the inclusion/exclusion criteria.
The IRT will assign a randomization number to the patient , which will be used to link the 
patient to a treatment arm and will specify  a unique medication number for the first package 
of study  treatment to be dispensed to the patient .The randomization number will not be 
communicated to the caller.
The randomization numbers will be generated using the following procedure to ensure that 
treatment assignment is unbiased and concealed from patients and investigator staff. A 
patient randomization list will be produced by the IRT provider using a validated system that 
automates the random assignment of patient numbers to randomization numbers. These 
randomization numbers are linked to the different treatment groups, which in turn arelinked 
to medication numbers. A separate medication list will be produced by or under the 
responsibility  of Novartis Drug Suppl y Management using a validated system that automates 
the random assignment of medication numbers to boxes containing the study  treatment. 
The randomization scheme for patient s will be reviewed and approved by a member of the 
Novartis Biometrics group.
5.3.1 Stratification
Randomization will be stratified by body weight.  The stratification ensures balanced 
allocation of patients to treatment groups within the weight strata.  The strata will be “bod y 
weight <90 kg” or “bod y weight ≥90 kg”.
Stratification by body weight will occur at Visit 2/Baseline.  The body  weight collected at 
Visit 2 will be used for the stratification.

Novartis Confidential Page 32
Amended Protocol Version 02 (Clean) Protocol No. CAIN457AUS07
5.4 Treatment blin ding
Patient s,investig a t ors/site staff,persons performing assessm ents, and Novartis study 
personnel will remainblinded t o individual treatment assignment fromthetime of
rando mization until the final database lock at Week 5 3,using thefollowing methods:
1.Randomization data willbekept str
ictlyconfidential untilthetime of unblinding, andwill 
not be accessible byanyoneelseinvolved inthestudy with thefollowing exceptions:
specific vendors whose roleintrialcondu ctrequires their unblinding (e.g., IRT)
Drug Supply  Management (DSM);
2.The identity  of secukinu mabandplacebo prefilled sy ringes (PFS) will be concealed by
identical packaging, labeling, schedule ofadministration, andappearance.
At the Week 12 primary analysis time point, there will be a database lock after all patient s 
have completed the Week 12 visit.  At that time, only  the statistician and programmer(s) from 
the designated CRO will be unblinded in order to perform the analysis.  Results from the 
analyses of all data through Week 12, including the data for the primary  efficacy  variable, will 
be reported.  For publication purposes, summary  results from the Week 12 primary  analysis 
time point may be shared with the health care community , however individual patient -level 
data will remain blinded until the end of the trial.
Unblinding will only occur in the case of patient emergencies (see Section 5.5.9), at the time 
of the primary  analysis (Week 12) for designated CRO personnel only, and at the conclusion 
of the study .
A
full analysi s of all data co llecteduptoWeek53 wi llb e performed when all patients ha ve 
completed Follow- up Visit 1/ Week53.
5.5 Treating the patient
Sponsor qualified medical personnel will be readily  available to advise on trial-related 
medical questions or problems.
5.5.1 Patient numbering
Each patient is uniquel y identified b y a Patient Number which is composed by  the site number 
assigned by Novartis and a sequen tial number assigned by the investigator.  Once assigned to 
a patient, the Patient Number will not be reused. 
Upon signing the informed consent form, the patient is assigned the next sequential number 
by the investigator.  The investigator or his/her staff will contact the IRT and provide the 
requested identify ing information for the patient to register them into the IRT.  The site must 
select the CRF book with a matching Patient Number from the EDC sy stem to enter data. 
If the patient fails to be treated for any  reason, the IRT s ystem must be notified that the patient
was not treated.  The reason for not being treated will be entered on the Screening Study 
Disposition eCRF.

Novartis Confidential Page 33
Amended Protocol Version 02 (Clean) Protocol No. CAIN457AUS07
5.5.2 Dispensing the study drug
Each study  site will be supplied by Novartis with secukinumab and placebo treatment in 
packaging of identical appearance.
The study  drug packaging has a 2-part label.  A unique medication number is printed on each 
part of this label which corresponds to one of the two treatment groups.  Inve stigator staff will 
identify  the study  drug package(s) to dispense to the 
patient by contacting the IRT and 
obtaining the medication number(s).  Immediately  before dispensing the package to the 
patient , investigator staff will detach the outer part of the label from the packaging and affix it 
to the source document (Drug Label Form) for that patient .
IRT will assign secukinum abor placebo ateach visit from Randomization toWeek48.  All 
boxes of study  treatment assigned by  the IRT will be recorded/databased in the I RT s ystem.
5.5.3 Handling of study  and additional treatment
5.5.3.1 Handling of study  treatment
Study  treatment must be received by a designated person at the study  site, handled and stored 
safel y and properl y, and kept in a secured location t
o which only the investigator and 
designees have access.  Upon receipt, all study treatment must be stored according to the 
instructions specified on the labels.  Clinical supplies are to be dispensed only in accordance 
with the protocol.  For anysyringe with atechnical issue, a description oftheissue must be
communicated toNovartisQualit y Assurance, and the syringe may be required to be 
returned to Novartis forfurther assess ment.  In the event a technical issue with a syringe is 
identified, site staff should contact their monitor for guidance on the reporting and returns 
process.
The prefilled syringes(150 mgsecukinumab or placebo) sealed intheir outer box must be
stored in a l ocked refrigerator between 2° to 8°C (36° to 46°F)and must be carefully
contr olledinaccordance with reg ulations governing inv e stigational medici nal products and
local regula tions.  Study treatment sh ould not b e frozen .  All temperature excursions 
(either below or above the required, specified temperature range) must be reported to Novartis 
for review and assessment of impact on the study  treatment.  In the event of a temperature 
excursion, site staff should contact their monitor for guidance on the reporting process.
Medication labels will be in English and will comply  with US legal requirements.  They will 
include storage conditions for the study  treatment but no information about the patient except 
for the medication number .
The investigator must maintain an accurate record of the shipment and dispensing of study 
treatm ent in a drug accountability  log.  Monitoring of drug accountability  will be performed 
by monitors during site visits or remotely , and at the completion of the trial.  Patient s will be 
asked to return all used/unused study  treatment and packaging to the st udy site.
At the conclusion of the study , and as appropriate during the course of the study , the 
investigator will return all used and unused study  treatment, packaging, drug labels, and a 
copy  of the completed drug accountability  log to the Novartis or re sponsible CRO monitor, or 
to the Novartis or responsible CRO address provided in the investigator folder at each site.

Novartis Confidential Page 34
Amended Protocol Version 02 (Clean) Protocol No. CAIN457AUS07
5.5.3.2 Handling of additional treatment
Not applicable.
5.5.4 Instructions for prescribing and taking study treatment
Alldoses ofstudy treatment thatareadministered atthestudy siteshould beperformed after 
allstudy assessments forthevisit have been completed.   The first study treatment 
administration will occur atVisit 2/Baseline after inclusion/exclusion criteria has
been confirmed and allscheduled assessments have beenperformed.
The prefilled syringes will be pr ovide d by the sitestaff tothepatient ,who will then self-
inject thestudy  treatment.  Site staff should remove the assigned study treatment from the 
refrigerator and allow the syringes to reach room temperature in their unopened box 
(approximately  15-30 minutes) before self -injection by  the patient.
Detailed instructions ontheself - administration ofthestudy treatment willbedescribed inthe 
Instructions For Use (IFU) , a copy of which will beprovided toeachpatient. Atthe
Baseline visit, the patient will be instructed bythe site staff (usingthe IFU) on how to self-
inject with the PFS.  Patient s will be asked to raise an y questions if they  have a ny.
Starting atVisit 3/Week 1, patient s willbe asked torefer totheIFU and toprocee d with self -
injection of the study treatment at the study  siteunder the supervision of site staff .
Patients must inject thestudy treatment intothe appropriate body  site (thighs, abdomen, 
upper outer arm).  Study treatment sh ould not be injected into ar eas where th e skin is tender,
b
ruised, red, scaly o r hard, or in an area of skin affected by psoriasis.  Areas with scars or
stretch marks sh ould be avoided.  As possible throughout thetrial, theinjection siteshould 
be rotated from visit to visit.
Allself-injections during the Double -blind Treatment Period will take place atthestudy
site; during the Double- blind Induction and Open -label Treatment Periods, self-injections will 
occur both at the stud y site and at home (refer to Table 6 -1).
Used study  treatment sy ringes should be
disposed immediately  afteruseinasharps container.
The investigator must promote compliance by instructing the patient to take the study 
treatment exactl y as prescribed and by stating that compliance is necessary  for the patient ’s 
safet y and the validit y of the study .  The patient must also be instructed to contact the 
investigator if he/she is unable for an y reason to ta ke the 
study treatment as prescribed.
Study treatment administration at home
If thepatient orcaregiver isnotable/confident t operform home administration, thepatient
willbe allowed toreturn tothe site for administration of the medication.  During those visits, 
no additional assessments will be require d.
Patients will be instructed to contact the investigator/site staff prior to self-administratio n at 
home ifthey are experiencing anyAE/SAEs or have anyconcerns.   Additionally , site staff 
will contact patients via telephone at the time of scheduled at-home dosing to check 
compliance and to ensure completion of the dosing log.

Novartis Confidential Page 35
Amended Protocol Version 02 (Clean) Protocol No. CAIN457AUS07
Patient s will be provided with the following items to facilitate the at-home injections of study  
treatment:  an insulated bag with cool gel packs to transport the study  treatment from the site to 
the patient ’s home; alcohol swabs and gauze pads; a sharps container for immediate disposal of 
the used syringes ; a copy of the IFU; and a paper Self-administration Logto record the dates 
and times of the at -home doses .
5.5.5 Permitted dose adjustments and interruptions of study  treatment
Study  treatment dose adjustments are not permitted.
Study  treatment interruption is permitted if, in the opinion of the investigator, a subject is 
deemed to be placed at a safet y risk 
unless dosing is temporarily  interrupted. In such cases 
study  treatment should be interrupted onl y during the time that this risk is present and ongoing. 
Study  treatment can be started again at the next scheduled visit after resolution of the safet y 
risk.
5.5.6 Rescue medication
Use of rescue medication is not permitted during the study . 
5.5.7 Concomitant treatment
The investigator must instruct the patient to notify  study staff about any new medications 
he/she takes after the patient was enrolled into the study . All medications, procedures and 
significant non-drug therapies (including physical therapy  and blood transfusions) 
administer ed after the patient was enrolled into the study  must be recorded in the Prior and 
Concomitant Medications eCRF or the Surgical and Medical Procedures eCRF as appropriate .
Each concomitant drug or therapy /procedure must be individually  assessed against all
exclusion criteria/prohibited medication. If in doubt the investigator should contact the study 
Medical Monitor before randomizing a patient or allowing a new medication or 
therap y/procedure 
to be started.
5.5.8 Prohibited medication
Use of the treatment s displayed in Table 5-2is NOT allowed for any indication after the 
start of study  treatment; the use of these treatments c ould conf ound the effic acy of the 
study  drug. Wash-out periods for these treatments ar e provid ed in Table 5-2. If the use of
any of t
hese treatments is r equired, then the patient must NOT be rando mizedinto the study.
The i nvestigator/qualified site staff must instruct the patient t o no tify them about anynew 
treatments he/she initiates during the study . All prohibited medi ca tions and significant
n
on-drug therapies administer eda fter the patient starts st udy treatment must b e listed on
the eCRF.
If a prohibited treatment li sted in Table 5-2is us edafter the start of study  treatment, the
patient must discontin ue use of the prohib ited treatment if he/she wishes to continue in the
s
tudy.
If, in the investigator’s clinical judgment, thepatient ’s use of a prohibited tr ea tment
presents an undue safet y risk for the patient, the patient must discontinue study treatmen t; ifa

Novartis Confidential Page 36
Amended Protocol Version 02 (Clean) Protocol No. CAIN457AUS07
patient receiv esalive virus v accination duri ngthe study, the patient m ustdiscontinu e study
t
reatmen t (see Section 5.6.2 ).
Table 5-2 Prohibited treatment
Prior Therapy (Before Visit 2/Baseline)
Prohibit edTreatm ents1,2Washout Period
(before Randomization)
Secukinumab No prior use allowed
Any biol ogic dru g directly tar getin g IL-17 or the IL-17 rec eptor
(e.g., ixekizumab or brodalumab)No prior use allowed
Alefac ept, briakinum ab, efalizuma b, ustekinumab 24weeks
Biologica l immunom odulating agen ts other than above
(e.g., adalimum ab, inf liximab, etanercept)12weeks
Other systemic i mmunom odulating tr eatm ents3[e.g., MTX,
cyclosporine A,corticosteroids (or al, i.v., tr ansdermal)3, 
cyclopho sphamide]4 weeks
Other systemic psoriasis tr eatm ents (e.g.,retinoid, fumarates) 4 weeks
Photo chemot herapy (e.g., PU VA) 4 weeks
Phototherapy (e.g., UVA, UV B) 2 weeks
Medicated psoriasis shampoo (including OTC) 2 weeks
Topica l treatm ent that is likely to im pact si gnsand symptoms o f 
psoriasis (e.g., vitami n D anal ogue s,pimecrolimus, ret inoids, 
salicylvase line, salicylic acid, lactic acid, ta crolimus, tar, ur ea,
α-hydroxy or fruit acid s)2 weeks
Topical Corticosteroids (TCS) any potency on areas of 
psoriasis2 weeks
Live virus vaccines 6 weeks
An investigational treatment or participation in any 
interventional trial4 weeks or 5 half -lives
(whichever is longer)
Any other treatment known to worsen psoriasis (e.g., beta -
blockers, calcium channel blockers)Stable dose for at least 4 weeks prior 
to randomization
Cholesterol -lowering medication (e.g., statins) Stable dose for ≥90 day s prior to 
randomization and remain stable for 
duration of the study
Concomitant Th erapy with TCS ( after Visit 2/Baseline)
Topical Corticosteroids (TCS) Concomitant Use
TCS on areas of psoriasis (including scalp) Hydrocortisone 2.5% cream is 
allowed on face and intertriginous 
areas ; medicated OTC shampoos are 
allowed for the scalp 
TCS m ild to m oderate potencyused for up to 7 consecutive 
days per event for an indication other than psoriasis and on 
areas notaffected by psoriasisAllowed during the study

Novartis Confidential Page 37
Amended Protocol Version 02 (Clean) Protocol No. CAIN457AUS07
1 If the prohi bited treatment was use d durin g the study for any indicati on, th e patient must disc ontinue u se of the 
prohi bited treatm ent ifhe/she wishes t o continue in the study.
2In case ofundue safety risk for th e patient as determined by the investigator, the patient should discontinue 
study tr eatm ent.If the patient receiv esalive virus vacci nation duri ng the study, the patient must disc ontinue 
study trea tment.
3InhaledCS wit h only a t opical e ffect(e.g., t o treat asthma) a re not c onsidered “system ic immunom odulating
treatm ents” and aretherefo re accept able a s c oncomitant medicati on.
5.5.9 Emergency  breaking of assigned treatment code
Emergency  code breaks must only be undertaken when it is required to in order to treat the 
patient safel y. Most often, study  treatment discontinuation and knowledge of the possible 
treatment assignments are sufficient to treat a study  patient who presents with an emergency 
condition. Emergency  treatment code breaks are performed using the IRT. When the 
investigator contacts the system to break a treatment code for a patient, he/she must provide 
the requested patient identify ing informat ion and confirm the necessity  to break the treatment 
code for the patient. The investigator will then receive details of the investigational drug 
treatment for the specified patient and a fax or email confirming this information. The system 
will automatica lly inform the Novartis monitor for the site and the Study Team that the code 
has been broken.
It is the investigator’s responsibility  to ensure that there is a dependable procedure in place to 
allow access to the IRT at any  time in case of emergency . The investigator will provide:
protocol number
study  drug name (if available)
patient number
In addition, oral and written information to the patient must be provided on how to contact 
his/her backup in cases of emergency , or when he/she is unavailable, to ensure that un-
blinding can be performed at an y time. 
Studytreatment mustbe discontinued after emergency unblinding.
The appropriate personnel from thestudy siteand Novartis will assess whether study 
treatment should be discontinued fora ny patient whose treatment code hasbeen broken 
inadvertent lyfor any reason
5.6 Stud y completion and d iscontinuation 
5.6.1 Study completion and post- study treatment
Apatient will beconsidered tohave completed thestudywhen (s)he hascompleted thelast 
visit planned in the protocol.
Continuing care should be provided by the investigator and/or referring physician based on 
patient availability  for follow -up.
5.6.2 Discontin uation of study t reatment
Discontinuation of study  treatment for a patient occurs when study  treatment is stopped earlier 
than the protocol planned duration, and can be initiated by  either the patient or the investigator.

Novartis Confidential Page 38
Amended Protocol Version 02 (Clean) Protocol No. CAIN457AUS07
Patient s may  voluntaril y discontinue study  treatment for an y reason at an y time.
The investigator must discontinue study  treatment for agiven patient if, on balance, he/she 
believes that continuation would negativel y impact the risk/benefit of trial participation.
Study  treatment must be discontinued under the following circumstances: 
Patient decision
Pregnancy  (see Section 6.7.5 and Section 7.4)
AEs that in the judgment of the investigator/qualified site staff, taking into account the 
patient ’s overall status prevent the patient from continuing study treatment
Any laboratory  abnormalities that in the judgment of the investigator, taking into 
consideration the 
patient ’s overall status, prevents the patient from continuing 
participation in the study
Ongoing use of prohibited treatment, use of a prohibited treatment that results in an undue
s
afety risk for the patient as per the investigator’s clinical judgment, or receipt of a live 
virus vaccine during the study (as detailed in Section 5.5.8)
Any situation in which study  participation might result in a safet y risk to the patient
Emergency  unblinding
The investigator /site staff must contact the IRT to register the patient’s discontinuation from 
study  treatment.
If study  drug discontinuati on occurs because treatment code has been broken, please refer to
Section 5.5.9.
5.6.2.1 End of treatment visit
Patient s who discontinue study  treatment should return to the study  site for an end of 
treatment visit. The end of treatment visit should be scheduled to occur approximately  four (4) 
weeks after the patient
’s last dose of study  treatment.   Discontinuation during:
Double -blind Treatment Period: For patient s who discontinue study  treatment 
prematurel y before the end of the Double -blind Treatment Period, the Visit 8/Week 12 
(EOT1) assessments should be performed.   
 
 
 
Double -blind Induction orOpen
-label Treatment Periods: For patient s who 
discontinue study  treatment prematurely  before the end of the Double -blind Induction or 
Open -label Treatment Periods, the Visit 15/Week 52 (EOT2) visit should be performed.
 
 
 
Assessments scheduled to be performed during the appropriate end of treatment visit per
Table 6-1should be completed and recorded intheeCRF. The investigator must determine

Novartis Confidential Page 39
Amended Protocol Version 02 (Clean) Protocol No. CAIN457AUS07
theprimar y reason forthepatient ’spremature study  discontinuation and record this 
information on the eCRF.
5.6.3 Withdrawal of informed consent
Patient s may voluntaril y withdraw consent to participate in the study  for any reason at any 
time.  Withdrawal of consent from the study  is defined as when a patient :
Does not want to participate in the study  anymore
and
Does not want an y further visits or assessm ents
and
Does not want an y further study related contacts
and
Does not allow anal ysis of already  obtained biologic material.
In this situation, the investigator must make every  effort (e.g. telephone, e-mail, letter) to 
determine the primary  reason for the patient ’s decision to withdraw his/her consent and record 
this information. 
Study  treatment must be discontinued and no further assessments conducted, and the data that 
would have been collected at subsequent visits will be considered missing. 
Further attempts to contact the patient are not allowed unless safety  findings require 
communicating or follow -up.
All efforts should be made to complete the assessments prior to study  withdrawal. A final 
evaluation at the time of the patient ’s study  withdrawal should be made as detailed in Table 6 -
1.
5.6.4 Loss to follow -up
For patient s whose status is unclear because they  fail to appear for study  visits without stating 
an intention to discontinue or withdraw, the investigator must show "due diligence" by 
documenting in the source documents steps taken to contact the patient
, e.g. dates of 
telephone calls, registered letters, etc. A patient cannot be considered as lost to follow -up 
until the time point of his/her scheduled end of study  visit has passed.
5.6.5 Early  study termination by  the sponsor
The study  can be terminated by Novartis at any time for any reason. This may include 
reasons related to the benefit risk assessment of participating in the st udy, practical reasons, or 
for regulatory  or medical reasons (including slow enrol lment). Should this be necessary , the 
patient must be seen as soon as possible and treated as a prematurel y withdrawn patient. The 
investigator may be informed of additiona l procedures to be followed in order to ensure that 
adequate consideration is given to the protection of the patient ’s interests. The investigator 
will be responsible for informing the Institutional Review Board/Independent Ethics 
Committee (I RBs/IECs) of the early  termination of the trial.

Novartis Confidential Page 40
Amended Protocol Version 02 (Clean) Protocol No. CAIN457AUS07
6 Visit schedule and assessments
Table 6-1lists all of the assessments and indicates with an “X” when the assessments are 
performed.   An “S” indicates the data for that assessment reside in the source documents at 
the site.
Patient
smust beseen forallvisits onthedesignated dayper the original planned 
visit schedule orasclose as possible to it.Ever y effortshould bemade torespect the
time fram eforallvisits, particularl ythe Week 12 and Week 52 visits.
6.1 Rescreening
Rescreening may be allowed under certain conditions.  Requests from the investigator/site 
staff to rescreen patient s will be handled on a case-by-case basis with Medical Monitor 
approval required before proceeding with the rescreening.  Rescreening cannot be done if a 
patient was previously  randomized into the study .
Ifa patient rescreens forthestudy
,thepatient mustsign a new ICF and be issued a new
patient number prior toany screening assessments beingconducted under the new patient
number.  The date of the new informed consent signature must be entered on the Informed 
consent eCRF to correspond to the new patient number. 
For rescreening, 
all screening assessments must beperformed perprotocol, except forthe
tuberculosis (TB) work up (ifapplicable). Ifthedate oftheTBwork upisless than 12
weeks from theprojected randomization date, then it is notrequired thatthe TB work up be
repeated; however, therescreened patient MUST repeat the QuantiFERON test performed by
the central laborator y.
6.2 Unscheduled visits
Patient s may be seen at any time foran unscheduled visit, e.g., i f they experience
deterioration ofpsoria sisorsuspected AEs. The assessments performed at an 
unscheduled visit areatthediscretion of the investigator/qualified sitestaff.  During
an unscheduled visit, study treatmentwillnot be admi nistered.

Novartis Confidential Page 41
Amended Protocol Version 0 2 (Clean) Protocol No. CAIN457AUS07
Table 6-1 Assessment schedule
Period
SCR Double -blind Treatment PeriodDouble -blind 
Induction 
PeriodOpen -label Treatment Period F-up
Unscheduled 
Visit2
NotesVisit 1 2 3 4 5 6 7 8/
EOT19 10 11 12 13 14 15/
EOT2 F11
Week -4 to BL BL 1 2 3 4 8 12 13 14 15 16 20 24 28 32 36 40 44 48 52 53
Assessment Day ≤-28 to BL 1 8 15 22 29 57 85 92 99 106 113 141 169 197 225 253 281 309 337 365 372
Obtain informed 
consentX
Demographics X See Section 6.4.1
Inclusion/exclusion 
criteriaX XSeeSection 4.1
andSection 4.2
Smoking and 
alcohol historyXSee Section 6.4.3
andSection 6.4.4
Psoriasis medical 
history/ prior
psoriasis therapiesX See Section 6.4.2
Cardiovascular 
medical historyX SeeSection 6.4.5
Other medical 
history/ current 
medical conditionsX SeeSection 6.4.6
Prior /concomitant 
medications /
Surgical and 
medical proceduresUpdate as necessary SeeSection 6.4.7
(s)AE assessment Update as necessary SeeSection 7
Physical 
examinationS S S S S S SeeSection 6.7.1
Height X See Section 6.7.3
Weight X X X X X X X X X X X X SeeSection 6.7.3
Waist 
circumferenceX X X X SeeSection 6.7.3

Novartis Confidential Page 42
Amended Protocol Version 0 2 (Clean) Protocol No. CAIN457AUS07
Period
SCR Double -blind Treatment PeriodDouble -blind 
Induction 
PeriodOpen -label Treatment Period F-up
Unscheduled 
Visit2
NotesVisit 1 2 3 4 5 6 7 8/
EOT19 10 11 12 13 14 15/
EOT2 F11
Week -4 to BL BL 1 2 3 4 8 12 13 14 15 16 20 24 28 32 36 40 44 48 52 53
Assessment Day ≤-28 to BL 1 8 15 22 29 57 85 92 99 106 113 141 169 197 225 253 281 309 337 365 372
BMI calculation X X X XSee Section 6.7.3 ; 
calculated in 
eCRF
Vital signs X X X X X X X X X X X X SeeSection 6.7.2
Lab analysis: 
Hematology3 X X X X XSeeSection 
6.7.4.1
Lab analysis: 
Clinical chemistry3 X X X X XSee Section 
6.7.4.2
hs-CRP3X X X X XSeeSection 
6.7.4.3
HbA1c3X X X X X XSeeSection 
6.7.4.4
Fasting labs: 
plasma glucose, 
insulin, lipid s3X X X X X XSeeSection 
6.7.4.5
HOMA -IR 
calculationX X X XSee Section 
6.7.4.5 ; calculated 
and reported by 
central lab
Serology lab 
analysis: HIV, Hep 
B and Hep C3X XSeeSection 
6.7.4.6
QuantiFERON® 
TB-Gold 
In-Tube test3X X See Section 6.4.8
Serum pregnancy 
test3 X X SeeSection 6.7.5
Urine pregnancy 
test (local)X X X X See Section 6.7.5

Novartis Confidential Page 43
Amended Protocol Version 0 2 (Clean) Protocol No. CAIN457AUS07
Period
SCR Double -blind Treatment PeriodDouble -blind 
Induction 
PeriodOpen -label Treatment Period F-up
Unscheduled 
Visit2
NotesVisit 1 2 3 4 5 6 7 8/
EOT19 10 11 12 13 14 15/
EOT2 F11
Week -4 to BL BL 1 2 3 4 8 12 13 14 15 16 20 24 28 32 36 40 44 48 52 53
Assessment Day ≤-28 to BL 1 8 15 22 29 57 85 92 99 106 113 141 169 197 225 253 281 309 337 365 372
PASI X X X X X X X X X X X X See Section 6.6.5
Alcohol and 
tobacco use 
assessmentsX X XSeeSection 6.4.3
andSection 6.4.4
Randomization via 
IRTS See Section 5.3
Patient self -
administration of 
study treatment at 
siteX X X X X X X X X X X X X SeeSection 5.5.4
Dispense study 
treatment to patient
for at-home dosingS S S S S See Section 5.5.4

Novartis Confidential Page 44
Amended Protocol Version 0 2 (Clean) Protocol No. CAIN457AUS07
Period
SCR Double -blind Treatment PeriodDouble -blind 
Induction 
PeriodOpen -label Treatment Period F-up
Unscheduled 
Visit2
NotesVisit 1 2 3 4 5 6 7 8/
EOT19 10 11 12 13 14 15/
EOT2 F11
Week -4 to BL BL 1 2 3 4 8 12 13 14 15 16 20 24 28 32 36 40 44 48 52 53
Assessment Day ≤-28 to BL 1 8 15 22 29 57 85 92 99 106 113 141 169 197 225 253 281 309 337 365 372
Patient self-
administration of 
study treatment at 
home and 
completion of Self -
Administration LogX X X X X XSee Section 5.5.4
and Section 6.5
At-home Dosing 
Phone Reminder S S S S S S See Section 6.5
Check Self -
Administration Log 
and returned 
used/unused study 
treatment and 
packagingS S S S S SeeSection 6.5
(S)AE = (serious) adverse event; BL = Baseline; BMI = body mass index; FACS = fluorescence activated cell sorting; F-up = Follow -upPeriod ; hs-CRP = high 
sensitivity C -reactive protein; HIV = human immunodeficiency virus; HOMA -IR = homeostatic model assessment of insulin resistance; IRT = interactive 
response technology; ; SCR = Screening; TB = tuberculosis; 
Weeks in dark/grey columns: At the seweeks, patient s are expected to self-administer the study treatment at home.   If the patient or caregiver cannot 
administer the drug at home, then the patient may return to the site for study treatment administration.
X= assessment to be recorded on clinical data base; S = assessment to be recorded in source documentation only
1.Patients who undergo skin biops iesat Visit 15/W eek 52 will return to the site for completion of V isit F1 ; additionally, all patients who discontinue prematurely from 
the study andwho undergo skin biopsies at their end of treatment visit (either Visit 8 /EOT1 or Visit 15 /EOT2) will return to the site for completion of Visit F1
2.Unscheduled Visit:  assessment(s) performed at a n unsc heduled visit are at the investigator’s discretion
3.Samples will be analyzed by a central laboratory

Novartis Confidential Page 45
Amended Protocol Version 0 2 (Clean ) Protocol No.CAIN457AUS07
Table 6-2 Assessment schedule for healthy  control cohort
Visit 1/EOT1F2 Notes
Obtain informed consent X
Demographics X See Section 6.4.1
Inclusion/exclusion criteria S See Section 3.1.6
Smoking and alcohol history X See Section 6.4.3 and Section 6.4.4
Cardiovascular medical history X See Section 6.4.5
Other medical history/ current medical 
conditionsX See Section 6.4.6
Prior/concomitant medications / 
Surgical and medical proceduresX See Section 6.4.7
(s)AE assessment X X See Section 7
Height X See Section 6.7.3
Weight X See Section 6.7.3
Waist circumference X See Section 6.7.3
BMI calculation X See Section 6.7.3 ; calculated in eCRF
Vital signs X See Section 6.7.2
Labanalysis: Hematology2X See Section 6.7.4.1
Lab analysis: Clinical chemistry2X See Section 6.7.4.2
hs-CRP2X See Section 6.7.4.3
HbA1c2X See Section 6.7.4.4
Fasting labs: plasma glucose, insulin, 
lipids2 X See Section 6.7.4.5
HOMA -IR calculation X See Section 6.7.4.5 ; calculated and reported by central lab
Urine pregnancy test (local) X See Section 6.7.5
(S)AE = (serious) adverse event; BMI = body mass index; FACS = fluorescence activated cell sorting; 
F2 = Follow -up Visit 2; hs-CRP = high sensitivity C -reactive protein; HOMA -IR = homeostatic model 
assessment of insulin resistance;  
X = assessment to be recorded on clinical data base; S = assessment to be recorded in source documentation 
only
1.Visit 1 assessments may or may not occur on the same day, however all assessments should be 
performed and completed within 7 calendar days of the informed consent date
2.Samples will be analyzed by a central laboratory
 

Novartis Confidential Page 46
Amended Protocol Version 0 2 (Clean ) Protocol No.CAIN457AUS07
6.3 Information to be collected on screening failures
All patient s who sign the informed consent butdiscontinue prior torandomization at Visit 
2/Baseline are considered to be screen failures.
If apatient discontinues prior torandomization, theIRT provider must benotified, and the 
reason forthe patient not being randomized will be entered on the Screening Phase
Disposition eCRF. TheScreening VisitDate,theDemograph y eCRF, theInformed Consent 
eCRF, the Inclusion/Exclusion eCRF , and the Subject Re-screening eCRF must becompleted. 
The Adverse Event eCRF should becompleted forany SAEs that occurred during the
screening period .  Adverse events that are notSAEs will befollowed by the investigator
andcollected only inthesource data.   TheWithdrawal of C onsent eCRF must be completed 
if consent was withdrawn during the screening period before the patient was randomized.
6.4 Patient demographics/other baseline characteristics
All baseline assessments will be performed prior to the first study  treatment administration.
6.4.1 Demographics
Patient
demographic data will be collected atVisit 1/Screening.  Data tobe collected on all
patient sinclude: date of birth, patient initials, age, sex, race, ethnicit y, and child -bearing 
potential (for females only ).
6.4.2 Psoriasis history  / Prior psoriasis therapies
Disease histor y willbecollected atVisit 1/Screening. The information tobecollected and 
entered inthePsoriasis History  eCRF and Prior Psoriasis Therap y eCRF includes the 
following:
start date ofplaque psoriasis;
previous psoriasis treatments ( including previous use of biologic therapies, as well as 
photothera p
yand/or photo chemothera py), duration of exposure, and the reason for 
discontinuation of each thera py;
presence of psoriatic arthritis and the date of first diagnosis ( by a phy sician).
6.4.3 Smoking history
The current and/or previous use of tobacco products will be recorded, as well as the estimated 
number of pack -
yearsbased on theapproximate consumption per yea r. Non-smokers will be 
advised to not start smoking during the study.
Current tobacco use will be assessed throughout the duration of the study  as the scheduled 
visits as indicated in Table 6-1.
6.4.4 Alcohol use history
The current and/or pr evious use of alcohol w ill be r ecorded. This includes the estimated 
number of alcoholic drinks consumed on average per day, and the date alcohol was last 
consumed.

Novartis Confidential Page 47
Amended Protocol Version 0 2 (Clean ) Protocol No.CAIN457AUS07
Current alcohol use will be assessed throughout the duration of the study  at the scheduled
visits as indicated in Table 6-1.
6.4.5 Comorbidities –cardiovascular history
Information pertaini ngt o cardiovascular medical his tory assess edprior to rando mization 
should b e reported on the Cardiovascular History  eCR F.
6.4.6 Relevant medical histor y/current medical conditions
Relevant medical history and current medical conditions prior to providing informed consent 
(not including psoriasis or psoriatic arthritis) will be recorded in th eMedical History  eCRF.
Whenever possible, diagnoses and not sym ptoms will be recorded.
Significant findings thatare observed after thepatient hassigned theinformed consent form 
and that meet the definition of an AE must be recorded in the AE eCRF. Investiga tor s will
have the discretion to r ecordabnormal test findings on the Medical Histor y eCR F when in
their judgment, the test a bn ormality occurred prior to the informed consen t s ignatur e.
6.4.7 Prior and concomitant medications
Concomitant medications and prior medications taken over the six (6) months p receding stud y 
enrollment will be captured inthe Prior and Concomitant Medication eCRFat the screening 
visit, and updated at Visit 2/Baseline.
6.4.8 Determination of tuberculosis status
Deter mination oftuberculosis (TB) status will berequired before adm
inistration ofstudy 
treatment. TBstatus must bedeter mined bymedi calhistory ,signs, s ymptom s,and TB
testing (QuantiFERON -TB G
oldassay ). Anysignif icant findings will be recorded inthe
appropriate eCRF(s), asnecessary .
IftheQuantiFERON -TB Gold Assay testispositi ve or indetermin a te,aTB workup should
beperformed asdefined bylocal guidelines todetermine thepatient ’s TB status.
6.4.8.1 QuantiFERON TB -Gold In -Tube assay
AQua
ntiFERON®TB-Gold In-Tube a ss ay w illbe p erformed toassess the TB status a t 
screening for all patient s . Th is test w ill only be used to deter mine patient’s eligib ility for th e 
trial. The test w ill be used to scr een the patient population for latent tuberculosis inf ec tion 
(Dohert y, Van Vorhees and L ebwohl 2008 ).
This blood-based a ssay is specific for Mycob ac terium tuberculosis and is not in fluen ced b y 
previ ou sBacillus Ca lmette-Guérin vaccination or exp osure to other Mycobacteria specie s.
T
his test, in contras t to the pu rified protein derivative ( PP D)skin test, is also ins ensitive to a 
booster e ffect since the patient is not expose d t o the v accine. The a ssay measures th e 
production of interferon-ga mma and presents it relative toa negative and a positive contro l 
sample ( Manuel and Kumar 2008).

Novartis Confidential Page 48
Amended Protocol Version 0 2 (Clean ) Protocol No.CAIN457AUS07
TheQuantiFERO N®-TB Gold assay test wi llbe supp liedbythe central laboratory. Details on 
the co llection, shipment of samples and reporting of results byt he central laborato ry are 
provided in the Laboratory Manual.
T
heresults of a TB workup forapatient with apositi ve or i ndeter minate tes t mustbe
recorded i n the eCRF.
If the tes t result is negat ive , the patient may b e randomized
If the tes t result is p ositive , the investi gator should perform a TB w orkup for the tes t result
as per l
ocal pro cedu res.
Patient
spositivefor latent TB perworkup may be rando mizedto the study if sufficient
treatment has been initiated acco rd ing to local rou tine c linical pr actice and will be
maintai nedfor the prescrib edduration.
Patient
spositivefor active TB perworkup are not eligible for the st udy.
Patients negat ivef or TB per workup (no signs of latent or active TB) may b e 
rando mized to thestudy .
If the tes t result is inde t erminate, it is recommended to rep eat the tes t once. Th e 
investi gator may decide to skip the repetition of the test and pro ceed directly to th e workup
(however this is not reco mmend ed). If a TB wor kupwasconducted prior toscreening,
r
esults from t he workup canbe us edtoass ess e ligibilityifthe wor kup was conducted
within 12 wee k s prior to rando mization.
If the second test is nega tive, th e patient may b e rando mized.
If the second test is p ositive or indeter minate, the investigator should perfor m a TB 
workup asperlocal guidelines. The patient w ill no t be eligible for rand omization if : 
“act
ive tuberculosis is presen t”,o r if “latent tu berculosis is p resent” and i s untr eated as
perlocal guide li nes.
Refer toSection 14 Appendix 2to see a schematic of the tuberculosis screening 
process and patient eligibility with respe cttoTBtesting.
6.4.9 Other baseline characteristics
Baseline char ac teristic data to be co llected on all patient s includ e (see also Table 6-1):
vital signs, hema tology , c linical chemistry , viral serology  (HIV, Hepatitis B and Hepatitis 
C), serum pregnancy , height, wei gh t;BMI, HOMA -IR, hs-CRP, HbA1c, PASI,  
.
6.5 Treatment exposure and compliance
All administered doses of secukinumab or pla cebo will be rec orded ontheDosage
A
dministration Record e CRF.  Compliance will beassessed at each visit byNovartis and 
CRO study personnel us ing the Dosage A dministration Record e CRF,medication numb ers,
Drug Label Form information, empt y medication boxes/outer packaging brought back to site
by patient ,andinfor mation collected byIRT.
Patient s will be provided with a Self -Administration L og at Visit 8/Week 12 to record the date 
and time of all at-home study  treatment administrations during the Double -blind Induction 
and Open -label Treatment Periods. 
Patient s will be instructed to return to the study  site at 

Novartis Confidential Page 49
Amended Protocol Version 0 2 (Clean ) Protocol No.CAIN457AUS07
each scheduled visit with their completed Self-Administration Log, where the dosing 
information will be transcribed by site staff into the Dosage Admi nistration Record e CRF.
Patient s will also be instructed to return all used/unused study  treatment and packaging to the 
study  site at each visit as part of the compliance check. The patient ’s Self-Administration Log 
will be retained in the patient’s source documents. 
The investigator/qualified site staff should promote compliance byinstructing patient sto 
attend thestudy visits asscheduled, totake thestudy treatments exactly asprescribed, andby 
reiterating thatcompliance is necessary forpatient safety andthevalidity ofthestudy .
Additionall y, site staff will contact patients via telephone at the time of scheduled at-
home dosing to check compliance and to ensure completion of the Self-Administration 
Log.  Likewise, patient sshould beinstructedtocontact thei nve stigator/qua lified sitestaff
ifhe/she isunable foranyreason toattend astudy visit asscheduled, orifhe/she isunable 
foranyreason to take the study treatmentathome asprescribed.
6.6 Efficacy
Primary  efficacy  variables are response of psoriasis skin lesions to treatment as measured b y :
Response in skin histology /K16 expression to treatment (y es, no)
PASI 90 (y es, no). 
The primary  anal ysis time point will be at Week 12.
Results for the data collected from the assessments in Section 6.6.2 and Section 6.6.3 below 
will be included as a separate appendix to the Clinical Study  Report (CSR).

Novartis Confidential Page 50
Amended Protocol Version 0 2 (Clean ) Protocol No.CAIN457AUS07

Novartis Confidential Page 51
Amended Protocol Version 0 2 (Clean ) Protocol No.CAIN457AUS07

Novartis Confidential Page 52
Amended Protocol Version 0 2 (Clean ) Protocol No.CAIN457AUS07
6.6.5 Assessment of total Body Surface A rea (BSA ) and Psoriasis Area and 
Severity Index (PA SI)
The investiga toror trained qualified designee will complete the PA SIassessment at scheduled 
visits as indicated in Table 6-1.  W henever p ossible, the same evaluator sh ould perfo rmthis
assessment at al l study  visit s for a given patient.
The total BSA a ff ected by pl aque psoriasi s will be estimated by the investigator/trained 
qualified designee from the pe
rcent ages of areasaffected,includi nghead, t runk, upper limbs
a
nd lo wer limbs (s eebelow for fu lldetails of the PASI a ssessment).  The following
c
alculation s will be don e electronically :  each r eported per centage will be multipli edbyits
respective b ody region co rresponding f actor (h ead=0.1, trun k=0.3, upper limbs=0 .2, lo wer
limbs=0 .4).  The resulting four per ce ntageswillbeadded upto estimate the total BSA
aff
ected by pl aque psoriasis.
APASI score (Fredriksson and Pettersson 1978 ,Weisman et al 2003 , Gottlieb et al 2005 )will 
be derived as indicated in Table 6 -4.  The head, trunk, upper limbs and lower limbs are 
assessed separatel yby the investigator/trained qualified designee forerythem a,thickening
(plaque elevation, induratio n), and scaling (desqua mation).   The average degree ofseverit y of
each sign ineach ofthefour body regions isassigned ascore of 0-4.   The area covered by
lesions oneach body region isestim
ated as a percentage of thetotal area ofthat particular 
body region.   The following practical details help the assess ment:
1. The neck is a ssessed as part of the h ead
2. The axillae and groin are a ssessed as part of the tr unk
3. The butto cks are a ssessed as part of the lo wer limbs
4. When scor ing the severity of erythema, scales sh ould not b e removed.
Becau se the h eadand n eck, upper limbs, trunk andl o werlimbs co rrespond toapproximatel y 
10%, 20%, 30% and 40% of the b ody surface area, respectively, the PASI score is calculat ed 
electronically within the eCRF using the following f ormul a:
PASI = 0.1(E H+ I H+D H)AH+ 0.2(EU+IU+D U)AU+ 0.3(ET+IT+D T)AT+ 0.4 (EL+ I L+D L)AL
The keys for the le tt ers are provided in Table 6 -4.
PASI scores canrange from a lower value of 0,corresponding tonosigns of psoriasis, up toa 
theoretic maximum of 72.0.
T
he baseline value for analysis of the PASI is co ll ected at Visit 2/Baseline .  A c opy of the 
PASI  worksheet is provided in Section 16 Appendix 4 .
Table 6-4 PASI scoring sy stem
Body region Erythema (E) Thickening -
plaque elevation, 
induration (I)Scaling –
desquamation 
(D)Area score –
based on true 
area % ( A)*
Head (H)†0=none 0=none 0=none 0=no involvem ent
1=slight 1=slight 1=slight 1=>0-<10%
2=moderate 2=moderate 2=moderate 2= 10-<30%
3=seve re 3=seve re 3=seve re 3=30-<50%

Novartis Confidential Page 53
Amended Protocol Version 0 2 (Clean ) Protocol No.CAIN457AUS07
Body region Erythema (E) Thickening -
plaque elevation, 
induration (I)Scaling –
desquamation 
(D)Area score –
based on true 
area % ( A)*
4=veryseve re 4=veryseve re 4=veryseve re 4=50-<70%
5=70-<90%
6=90-100%
Trunk (T)‡0=none 0=none 0=none 0=no involvem ent
1=slight 1=slight 1=slight 1=>0-<10%
2=moderate 2=moderate 2=moderate 2= 10-<30%
3=seve re 3=seve re 3=seve re 3=30-<50%
4=veryseve re 4=veryseve re 4=veryseve re 4=50-<70%
5=70-<90%
6=90-100%
Upper 0=none 0=none 0=none 0=no involvem ent
limbs (U) 1=slight 1=slight 1=slight 1=>0-<10%
2=moderate 2=moderate 2=moderate 2= 10-<30%
3=seve re 3=seve re 3=seve re 3=30-<50%
4=veryseve re 4=veryseve re 4=veryseve re 4=50-<70%
5=70-<90%
6=90-100%
Lower 0=none 0=none 0=none 0=no involvem ent
limbs (L)§1=slight 1=slight 1=slight 1=>0-<10%
2=moderate 2=moderate 2=moderate 2= 10-<30%
3=seve re 3=seve re 3=seve re 3=30-<50%
4=veryseve re 4=veryseve re 4=veryseve re 4=50-<70%
5=70-<90%
6=90-100%
*Percentage ( not score) of body regio n (not w hole body) affecte d will b e entered in th e eCRF
†Neckis assesse d aspartof the Head (H)body regi on
‡Axillaeand groin areassesse d aspartof the Tr unk (T) body r egion
§Buttocks a re assessed aspartof the Lower limbs (L) b ody r egion
Definitions of efficacy variables based on PA SI
The following definitions w illb e used in this st udy b ased on the CHMP guidelines fo r 
psoriasis ( CHMP/EWP/2454/02 2004 ) :
  
PASI 90 response :patient sachieving ≥90% im provement (reduction) in PA SIscore 
compar edtobaseline are defi nedasP A SI90 responders


Novartis Confidential Page 54
Amended Protocol Version 0 2 (Clean ) Protocol No.CAIN457AUS07
6.6.6 Appropriateness of efficacy  assessments
Determining the response of skin to psoriasis treatment, by using combined genetic studies 
including microarray  technology  with histopathology  over the course of anti-TNF alpha 
treatment (etanercept ) and anti-IL-17A (ixekizumab) treatment has been used previously  and 
are well established methodology  (Zaba et al 2007 ;Zaba et al 2009 ;Wang et al 2014 ).
 
 
Flow cytometry  has been used to measure T-cell activation for skin diseases such as atopic 
dermatitis and psoriasis ( Czarnowicki et al 2015 ) .
The PASI  is a standard and validated measurement for chronic plaque psoriasis.
 
 
6.7 Safet y
All blood dr aws and safet y assessments must be performed prior tos t udy treatment
administration.  Appropriate safet y assessments (e.g., evaluation of AEs and SAE s including 
injection site reactions ) should b e repeated afte r d osing with study treatmen t.
6.7.1 Physical examination
The physical examination, including general appearance, will be performed at the scheduled 
study  visits as indicated in Table 6 -1.
The physical examination is performed by a  p rofessionall y trained physician or health 
professional licensed to perform ph ysical examinations, and listed on FDA Form 1572. 
Ifindicated, based onmedical history and/or symptoms, additional exams will be
performed at the discretion of the investigator.
Ifpossible, assessments foranindividual patient should b eperforme d by thesamemembe rof 
thestudy site staff throughout the stud y.
Informatio n for all physical examinations must be included in the source documentation at the 
study site.  Significant findings thatarepresent prior tothepatient signing informed consent 
must beincluded intheMedical History eCRF.  Significant findings made afterthesigning
of the informed consent which meet thedefinition of anAE (see Section 
7) must berecorded
on the AE eCRF .

Novartis Confidential Page 55
Amended Protocol Version 0 2 (Clean ) Protocol No.CAIN457AUS07
6.7.2 Vital signs
Vital signs will be performed at the scheduled study  visits as indicated in Table 6-1.  Vital 
signs include blood pressure (BP) and pulse measurements. BP will be measured using a 
standard sph ygmomanomete r with an appropriate sized cuff.
All clothing that covers the location of the cuff placement is to be removed by the patient .  
The patient should be asked to sit comfortabl y with the back supported and legs uncrossed; 
the arm should be supported so that the middle of the cuff is level with the right atrium (mid -
point of the sternum).  The patient should be instructed not to talk and relax as much as 
possible while the measurement is being taken.  The measurement should be taken after the 
patient has been in a seated position and has been resting for 5 minutes ( Pickering et al 2005).  
Every  effort should be made to use the same arm for the 
patient for all vital signs assessments 
and where possible, the same person performing the assessment.
N
ormal bl ood pre ssure wi llb e defi nedasa sys tolic pre ssure of 90 to<120 mm Hg, anda 
diasto lic bl ood pre ssure of 60 to <80 m mHgunderthe m easurement conditions out lined 
above. Notable bl ood pre ssure w il l be hypertension (sys tolic bl ood pre ssure of ≥140 mmHg 
and/or dias tolic b lood pre ssure of ≥90 mm Hg)or hypot e nsion (sys tolic blood pre ssure o f 
<90 mm
Hgand/or a dias toli c blood pre ssure of <60 mm Hg). A b lood pre ssure indi ca tive
of prehy pertension (sys tolic bl ood pre ssure o f 120 to <140 mm Hg and/o r diastolic bl ood 
pressure of 80 to <90 mmHg)w illnot b e regar dedasnotable (Chobanian et al 2003).
A norma l pulse rate wi llb e defin edasa rate of 60 to100 b eats perminute (bpm) under th e 
measuremen t c ondition s outlined abov e. Notable pulse r ate s are a rate belo w 60 bpm 
(brady cardia) or above 100 bpm (t achycardia).
Whether action n eeds to be ta ken toaddress not abl e v ital sign s values willbe deci dedbythe 
investiga tor , t aking into account th e overall status of th e patient . No specifi c action i s pre-
defined aspart of the study protocol.
6.7.3 Height and weight and waist circumference
The measurements will be performed at scheduled visits as indic
ated in Table 6-1.
Height in centimeters (cm) and body  weight (to the nearest 0.1 kilogram (kg) in indoor 
clothing, but without shoes) will be measured. Thebody w eight recor ded at Visit 2/Baseline 
will beused tostrati fyrandomi zation atVisit2.
Waist circumference to the nearest centimeter (cm) will be measured using a tape measure.  
Starting at the top of the hip bone, bring the tape measure all the way  around so that it is level 
with the belly  button.  Make sure the tape measure is not too tight and that it is straight.  The 
patient should be instructed not to hold their breath during the measurement.
Body Mass Index (BMI) will be calculated within the eCRF.
6.7.4 Laboratory  evaluations
Laboratory  evaluations will be performed at the scheduled study  visits as indicated in Table 6 -
1.

Novartis Confidential Page 56
Amended Protocol Version 0 2 (Clean ) Protocol No.CAIN457AUS07
Acentral laborator y will be used foranalysisofallspecimens unless noted otherwise. 
Details onthecollections, shipment ofsamples and reporting ofresults by thecentral
laboratory are provided to investigators in the L aborator yManual.
RefertotheLaboratory Manual for ide ntif ication oflaborat ory re ference ra nges, and notable 
values.
Whether or not any action needs tobetaken toaddress notable labor atory values will be 
determined bytheinvestigator/qualified site staff, taking intoaccount theoverall status ofthe
patient
.  No specific action ispre-defined within this study protocol.
6.7.4.1 Hematology
Hematology  assessments will be performed at the scheduled visits as indicated in Table 6-1
and include: hemoglobin, hematocrit, redbloodcell count, white blood cell count with 
differential (neutrophils including bands, lymphoc ytes,monoc ytes, eosinophils, basophils)
andplatelet count.
6.7.4.2 Clinical chemistry
Serum chemistry  panel will be performed at the scheduled visits as indicated in Table 6-1and 
include
s:urea, creatinine, total bilirubin, alanine transaminase (ALT )/serum glutamic 
pyruvate transaminase (SGPT), aspartate transaminase (AST)/serum glutamic oxaloacetic
transaminase (SGOT), gamma gluta myltranspeptidatse (GGT), and alkaline phosphatase .
6.7.4.3 High -sensitivity  C-reactive protein
High -sensitivity  C-reactive protein (hs-CRP) will be measured by the central laboratory  at the 
scheduled visits as indicated in Table 6-1.
6.7.4.4 Hemoglobin A 1c
Hemoglobin A1c (HbA1c) will be measured by the central laboratory  at the scheduled visits 
as indicated in Table 6 -1.
6.7.4.5   
Fasting laboratory  evaluations and HOMA -IR
Fasting ( minimum 8 hour duration with water ad libitum ) laboratory  tests will be performed at 
scheduled visits as indicated in Table 6-1 and will include:
plasma glucose
insulin
lipids
Homeostatic model assessment of insulin resistance (HOMA -IR) values will be reported by 
the central laboratory  at 
the scheduled visits as indicated in Table 6 -1.
6.7.4.6 Viral serology
Viral serology  will be performed at screening and will include:

Novartis Confidential Page 57
Amended Protocol Version 0 2 (Clean ) Protocol No.CAIN457AUS07
Hepatitis screening: Hepatitis B surface antigen (HBsAg) ; Hepatitis C virus antibody 
(HCVAb)
HIV screening: HIV 1/2
6.7.5 Pregnancy  and assessments of fertility
All pre-menopausal women who are not surgically  sterile will have a serum β-hCGtest
performe datscreening (Visit 1) . 
All women of childbearing potential will also have a urine pregnancy testperformed locally at 
Visit 2/B aseline. Visit 8/Week 12, and Visit 15/Week 52.
Any woman with a confirmed positive pregnancy  testduring screening isnoteligible for 
randomization.
A positive urine pregnancy  test during the study  requires immediate interruption of study 
treatment until serum β-hC G is performed and found to be negative. If the serum β-hC G test 
is positive, the patient must be discontinued from the study  as described in Section 5.6.2.
6.7.6 Appropriateness of safety  measurements
The safet y assessments selected for 
this study are reliable and standard measures for a 
biologic immunomodulating agent in adult patients with psoriasis.
6.8 Other assessments
No additional tests will be performed on patient s entered into this study .
7 Safety  monitoring
7.1 Adverse events
An adverse event (AE) is any untoward medical occurrence (e.g., any unfavorable and 
unintended sign [including abnormal laboratory  findings], symptom or disease) in a patient or 
clinical investigation patient after providing written informed consent for participation in the 
study  until the end of study  visit. Therefo re, an AE may or may  not be temporally  or causally 
associated with the use of a medicinal (investigational) product.
In addition, all reports of intentional misuse and abuse of the product are also considered an 
adverse event irrespective if a clinical eve nt has occurred.
The occurrence of adverse events must be sought by non-directive questioning of the patient
at each visit during the study .Adverse events also may be detected when they are 
volunteered by the patient during or between visits or through physical examination findings, 
laboratory  test findings, or other assessments.
Abnormal laboratory  values or test results constitute adverse events only if they fulfill at least 
one of the following criteria:
they induce clinical signs or sy mptoms, 
they are considered clinically  significant, 

Novartis Confidential Page 58
Amended Protocol Version 0 2 (Clean ) Protocol No.CAIN457AUS07
they require therapy . 
Clinically  significant abnormal laboratory  values or test results must be identified through a 
review of values outside of normal ranges/clinically  notable ranges, significant changes from 
baseli ne or the previous visit, or values which are considered to be non-typical in a patien t 
with underl ying disease. Investigators have the responsibility  for managing the safet y of 
individual patient sand identify ing adverse events. Alert ranges for laboratory  and other test 
abnormalities are included in Section 13 Appendix 1 .
Adverse events must be recorded in the Adverse Events CRF under the signs, symptoms or 
diagnosis associated with them, accompanied by the following information:
the severit y grade
mild: usually  transient in nature and generally  not interfering with normal activities
moderate: sufficiently  discomforting to interfere with normal activities
severe: prevents normal activities
its relationship to the study  treatment
Yes
No
its duration (start and end dates) or if the event is ongoing ,an outcome of not 
recovered/not resolved must be reported
whether it constitutes a serious adverse event (SAE -
see Section 7.2 for definition of SAE) 
and which seriousness criteria have been met
action taken regarding study treatment 
All adverse events must be treated appropriatel y. Treatment may include one or more of 
the following: 
no action taken ( e.g. further observation only ) 
study treatment dosage increased/reduced
study treatment interrupted/withdrawn
concomitant medication
non-drug therap y given 
patient hospitalized/ patient ’s hospitalization prolonged (see Section 7.2 for definition of 
SAE)
its outcome (not recovered/not resolved; recovered/resolved; recovering/resolving, 
recovered/resolved with sequelae; fatal; or unknown)
Once an adverse event is detecte d, it must be followed until its resolution or until it is judged 
to be permanent, and assessment must be made at each visit (or more frequently , if necessary ) 
of any changes in severity , the suspected relationship to the study  drug, the interventions 
required to treat it, and the outcome.
Worsening ofpsoriasis inthis studyisevaluated via
theuseofthe PASI 
and isnot ex pected tobecaptured asanAE intheeCRF.  Exceptions include 
cases where:  a) anew type ofpsoriasis isdiagnosed, e.g. guttate psoriasis, or b) the 
worsening of psoriasis is so severe that a qualitatively different status is reached.

Novartis Confidential Page 59
Amended Protocol Version 0 2 (Clean ) Protocol No.CAIN457AUS07
Information about common side effects alread y known about the investigational drug can be 
found in the Investigator Brochure (IB). This information will be included in the patient
informed consent and should be discussed with the patient during the study  as needed. Any 
new information regarding the safet y profile of the medicinal product that is identified 
between IB updates will be communicated as appropriate, for example, via an Investigator 
Notification or an Aggregate Safet y Finding. New information might require an update to the 
informed consent and has then to be discussed with the patient .
The investigator must also instruct each patient to report any new adverse event (beyond the 
protocol observation period) that the patient , or the patient ’s personal physician, believes 
might reasonabl y be related to study  treatment. This information must be recorded in the 
investigator’s source documents; however, if the AE meets the criteria of an SAE, it must be 
reported to Novartis.
7.2 Serious adverse events
7.2.1 Definition of SA E
An SAE is defined as any adverse event [appearance of (or worsening of any pre-existing )]
undesirable sign(s), symptom(s) or medical conditions(s)) which meets any one of the 
following criteria:
is fatal or life -threatening 
results in persistent or significant disability /incapacity
constitutes a congenital anomaly /birth defect
requires inpatient hospitalization or prolongation of existing hospitalization, unless 
hospitalization is for:
routine treatment or monitoring of the studied indication, not associated with any  
deterioration in condition (specify  what this includes)
elective or pre -planned treatment for a pre -existing condition that is unrelated to the 
indication under study  and has not worsened since signing the informed consent
treatment on an emergency  outpatient basis for an event not fulfilling any of the 
definitions of a SAE given above and not resulting in hospital admission 
social reasons and respite care in the absence of any  deterioration in the patient’s 
general condition
is medically  significant, e.g. defined as an event that jeopardizes the patient or may  
require medical or surgical intervention.
All malignant neoplasms will be assessed as serious under “medically  significant” if other 
seriousness criteria are not met.
Life-threatening in the context of a SAE refers to a reaction in which th e patient was at risk of 
death at the time of the reaction; it does not refer to a reaction that hypothetically  might have 
caused death if it were more severe ( please refer to Annex I V, ICH -E2D Guideline).
Medical and scientific judgment should be exercise d in deciding whether other situations 
should be considered serious reactions, such as important medical events that might not be 
immediately  life threatening or result in death or hospitalization but might jeopardize the 

Novartis Confidential Page 60
Amended Protocol Version 0 2 (Clean ) Protocol No.CAIN457AUS07
patient or might require intervent ion to prevent one of the other outcomes listed above.
Examples of such events are intensive treatment in an emergency  room or at home for allergic 
bronchospasm, blood dyscrasias or convulsions that do not result in hospitalization or 
development of depen dency  or abuse ( please refer to Annex I V, ICH-E2D Guideline).
Any suspected transmission via a medicinal product of an infectious agent is also considered a 
serious adverse reaction.
7.2.2 SAE reporting
To ensure patient safet y, every SAE, regardless of causalit y, occurring after the patient has 
provided informed consent and until 30 days after the last study  visitmust be reported to 
Novartis safet y within 24 hours of learning of its occurrence. Any SAEs experienced aft er the 
30 day period after the last study  visit should only be reported to Novartis safet y if the 
investigator suspects a causal relationship to study treatment. 
All follow -up information for the SAE including information on complications, progression of 
the initial SAE ,and recurrent episodes must be reported as follow -up to the original episode 
within 24 hours of the investigator receiving the follow -up information. An SAE occurring at 
a different time interval or otherwise considered completely  unrelat ed to a previously  reported 
one must be reported separatel y as a new event.
Information about all SAEs is collected and recorded on the Serious Adverse Event Report 
Form; all applicable sections of the form must be completed in order to provide a clinicall y 
thorough report. The investigator must assess the relationship of each SAE to study  treatment, 
complete the SAE Report Form in English, and submit the completed for m within 24 hours to 
Novartis. Detailed instructions regarding the submission process and requirements for 
signature are to be found in the investigator folder provided to each site. 
Follow -up information is submitted as instructed in the investigator folder. Each re-
occurrence, complication, or progression of the original event must be rep orted as a follow -up 
to that event regardless of when it occurs. The follow -up information should describe 
whether the event has resolved or continues, if and how it was treated, whether the blind was 
broken or not, and whether the patient continued or withdrew from study  participation.
If the SAE is not previously  documented in the Investigator’s Brochure or Package Insert 
(new occurrence) and is thought to be related to the study  treatment ,a Drug Safet y and 
Epidemiology  Department associate may urgent ly require further informa tion from the 
investigator for health authority  reporting. Novartis may need to issue an Investigator 
Notification (IN) to inform all investigators involved in any study with the same study  
treatment that this SAE has been report ed. Suspected Unexpected Serious Adverse Reactions 
(SUSARs) will be collected and reported to the competent authorities and relevant ethics 
committees in accordance with EU Guidance 2011/C 172/01 or as per national regulatory 
requirements in participating countries.
7.3 Reporting of study  treatment errors including misuse/abuse
Medication errors are unintentional errors in the prescribing, dispensing, administration or 
monitoring of a medicine while under the control of a healthcare professional, patient or 
consumer (EMA definition).

Novartis Confidential Page 61
Amended Protocol Version 0 2 (Clean ) Protocol No.CAIN457AUS07
Misuse refers to situations where the medicinal product is intentionally  and inappropriatel y 
used not in accordance with the protocol.
Abuse corresponds to the persistent or sporadic, intentional excessive use of a medicinal 
produc t, which is accompanied by  harmful ph ysical or psy chological effects.
Study  treatment errors and uses outside of what is foreseen in the protocol will be collected in 
the Dose Administration Record eCRF irrespective of whether or not associated with an 
AE/SAE ,and reported to Safet y only if associated with an SAE. Misuse or abuse will be 
collected and reported in the safety  database irrespective of it being associated with an 
AE/SAE.
Table 7- 1 Guidance for capturing the study  treatment errors including 
misuse/abuse
Treatment error 
typeDocument in Dose 
Administration (DA R) 
eCRF (Yes/No)Document in A E 
eCRFComplete SA E form
Unintentional study 
treatment errorYes Only if associated with 
an AEOnly if associated with an 
SAE
Misuse/Abuse Yes Yes, Yes, even if not associated 
with a SAE
7.4 Pregnancy  reporting
To ensure patient safet y, each pregnancy  occurring after signing the informed consent must be 
reported to Novartis within 24 hours of learning of its occurrence. The pregnancy  should be 
followed up to determine outcome, including spontaneous or voluntary  termination, details of 
the birth, and the presence or absence of any birth defects, congenital abnormalities, or 
maternal and/or newborn complications.
Pregnancy  must be recorded on the Pharmacov igilance Pregnancy  Form and reported by the 
investigator to the local Novartis Drug Safet y and Epidemiology  Department. Pregnancy 
follow -up should be recorded on the same form and should include an assessment of the 
possible relationship to the study  treatment.
Any SAE experienced during the pregnancy  and unrelated to the pregnancy  must be reported 
on an SAE form.
8 Data revie w and database management
8.1 Site monitoring
Before study  initiation, at a site initiation visit or at an investigator’s meeting, a Novar tis 
representative will review the protocol and data capture requirements with the investigators 
and their staff. During the study , Novartis employ s several methods of ensuring protocol and 
GCP compliance and the quality /integrit y of the sites’ data. The field monitor will visit the 
site to check the completeness of patient records, the accuracy  of data capture / data entry , the 
adherence to the protocol and to Good Clinical Practice, the progress of enrollment, and to 
ensure that study  treatment is being stored, dispensed, and accounted for according to 

Novartis Confidential Page 62
Amended Protocol Version 0 2 (Clean ) Protocol No.CAIN457AUS07
specifications. Key study personnel must be available to assist the field monitor during these 
visits.  Continuous remote monitoring of each site’s data may be performed by a centralized 
Novartis CRA organization. Additionally , a central analytics organization may analyze data 
andidentify  risks andtrends for site operational parameters, and provide reports to Novartis 
Clinical Teams to assist with trial oversight.
The investigator must maintain source documents for each patient in the study , consisting of 
case and visit notes (hospital or clinic medical records) containing demographic and medical 
information, laboratory data, electrocardiograms, and the results of any other tests or 
assessments. All information on eCRFs must be traceable to these source documents in the 
patient's file. The investigator must also keep the original informed consent form signed by 
the patient (a signed copy  is given to the patient ).
The investigator must give the monitor access to all relevant source documents to confirm 
their consistency  with the data capture and/or data entry .Novartis monitoring standards 
require full verification for the presence of informed consent, adherence to the 
inclusion/exclusion criteria, documentation of SAEs, and of data that will be used for all 
primary  variables. Additional checks of the consistency  of the source data with the eCRFs are 
performed according to the study -specific monitoring plan. No information in source 
documents about the identity  of the patient s will be disclosed.
8.2 Data collection
The trial (including the control cohort of healthy volunteers) will be conducted in a fully 
validated Data Capture system which conforms to US CRF 21 Part 11 requirements. 
Investigator site staff will not be given access to the system until they have been trained. 
Designated investigator staff will enter the data req uired by  the protocol into the Data Capture 
system. Automatic validation programs within the system check for data discrepancies in the 
CRFs and by generating appropriate error messages, allow the data to be confirmed or 
corrected by the investigator staff. The investigator staff must certify  that the data entered are 
complete and accurate. After database lock, the investigator will receive copies of the patient 
data for archiving at the investigational site.
Designated investigator staff will enter the data required by the protocol into the OC/RDC 
system. Designated investigator site staff will not be given access to the system until they 
have been trained. 
Automatic validation procedures within the system check for data discrepancies during and 
after data entry  and, by generating appropriate error messages, allow the data to be confirmed 
or corrected online by the designated investigator site staff. The Investigator must certify  that 
the data entered into the electronic Case Report Forms are complete and accurate. After 
database lock, the investigator will receive copies of the patient data for archiving at the 
investigational site.
8.3 Database management and quality  control
Novartis staff [or CRO working on behalf of Novartis] review the data entered into the CRFs 
by investigational staff for completeness and accuracy  and instruct the site personnel to make 
any required correc tions or additions. Queries are sent to the investigational site using an 

Novartis Confidential Page 63
Amended Protocol Version 0 2 (Clean ) Protocol No.CAIN457AUS07
electronic data query . Designated investigator site staff is required to respond to the query 
and confirm or correct the data. If the electronic query  system is not used, a paper Data Query 
Form will be faxed to the site. Site personnel will complete and sign the faxed copy  and fax it 
back to Novartis staff that will make the correction to the database. The signed copy of the 
Data Query  Form is kept at the investigator site.
Concomitant medications entered into the database will be coded using the WHO Drug 
Reference List, which employ s the Anatomical Therapeutic Chemical classification system. 
Concomitant procedures, non-drug therapies and adverse events will be coded using the 
Medical dictionary  for regulatory  activities (MedDRA) terminology .
Laboratory  samples will be processed centrall y and the results will be sent electronicall y to 
Novartis (or a designated CRO).
Randomization codes and data about all study  drug(s) dispensed to the patient and all dosage 
changes will be tracked using an Interactive Response Technology  (IRT). The system will be 
supplied by a vendor, who will also manage the IRT database. The database will be sent 
electronically  to Novartis (or a designated CRO).
Each occurrence of a code break via IRT will be reported to the clinical team and monitor.  
The code break functionality  will remain available until study  shut down or upon request of 
Novartis. 
The occurrence of relevant protocol deviations will be determ ined. After these actions have 
been completed and the database has been declared to be complete and accurate, it will be 
locked and the treatment codes will be unblinded and made available for data analysis. Any 
changes to the database after that time ca
n onl y be made after written agreement by Novartis 
Development management.
8.4 Data Monitoring Committee
Not required.
8.5 Adjudication Committee
Not required.
9 Data analy sis
A designated Contract Research Organization will perform the statistical analy sis.
It is p lanned that the data from all centers that participate in this protocol will be combined, so 
that an adequate number of patient s will be available for analy sis.
The analy sis will be conducted on all patient data at the end of Week 12 and at the time the 
trial ends at Week 53. Any data analysis carried out independently  by the investigator should 
be submitted to Novartis before publication or presentation.
Efficacy , safet y, and other data will be summarized for all weeks up to Week 53.  For 
continuous varia bles, summary  statistics (mean, standard deviation, median, 25th and 75th 
percentiles, interquartile range, minimum, and maximum) at each time point and for change 

Novartis Confidential Page 64
Amended Protocol Version 0 2 (Clean ) Protocol No.CAIN457AUS07
from baseline to each time point will be reported by treatment group.  For discrete variable s, 
frequency  counts and percentages at each time point will be reported by  treatment group.
Primary   efficacy  variables will be summ arized for lesional  
sample s.
9.1 Analysis sets 
The following anal ysis sets will be used for the statistical reporting and analy ses:
Randomized Set: The Randomized Set includes all randomized patient s.  
Safety  Set: The Safety  Set includes all patients who received at least one dose of study 
medication.  Patient s will be included in the analy sis according to treatment received.
Full Analy sis Set:  The Full Analy sis Set comprises all patient s to whom study  medication has 
been assigned.  Patient s inappropriatel y randomized (e.g., IRT was called in error for 
randomization of a screen failed patient ) will be excluded from this analysis set.  Following  
the intent -to-treat principle, patient s will be analy zed according to the treatment they were 
assigned to at randomization.
9.2 Patient demographics and other baseline characteristics
Data will be summarized by stratumwith respect to demographic and baseline characteristics 
of all patient sfor the Randomized Set and the Full Analy sis Set.
9.3 Treatments
The number of patients and the length of time (in day s) exposed to each treatment will be 
summarized for the Safety  Set.
Concomitant medications will be summarized by treatment using frequency  counts and 
percentages for the Safety Set.
Any condition entered as medical history  or current medical condition at baseline will be 
coded using the MedDRA dictionary  for the Safety  Set. They  will be summarized by system 
organ class and preferred term of the MedDRA dictionary .
9.4 Analysis of the primary  variable(s)
9.4.1 Variable(s)
Response of psoriasis skin lesions to treatment as measured b y:
a.Response in skin histology /K16 express ionto treatment (y es, no)
b.PASI 90 (y es, no) 
The primary  anal ysis time point will be at Week 12.
9.4.2 Statistical model, hypothesis, and method of analy sis
For the two primary  efficacy  variables at each time point (response inskin histology /K16 
expression to treatment at Week 12, PASI  90 at Weeks 4, 8, and 12) , 95% confidence interval 

Novartis Confidential Page 65
Amended Protocol Version 0 2 (Clean ) Protocol No.CAIN457AUS07
for the difference between the two treatment groups with respect to the percentage of patients 
who have the “event” will be calculated using the normal approximation to the binom ial 
distribution.
The primary  anal ysis of the primary  efficacy  variables will be based on the Full Anal ysis Set.
9.4.3 Handling of missing values/censoring/discontinuations
For the two primary  efficacy  variables at Week 12 (and other time points), a patient with a 
missing assessment will be considered as a non -responder.
9.4.4 Sensitivity analy ses
The two primary  efficacy  variables will be analyzed at each time point for the Full Anal ysis 
Set using a logistic regression model with treatment and body  weight (<90 kg, ≥90 kg) as 
explanatory  variables (Stokes, Davis, and Koch, 2012 ).  The odds ratios and 95% confidence 
intervals for the odds ratios based on the fitted model will be
 reported.
Estimates of differences between the two p roportions within each stratumwill be calculated 
and examined for meaningful treatment -by-stratum interaction.
9.5 Analysis of secondary  variables
9.5.1 Efficacy  variables
The secondary  efficacy  objective (i.e., explore the modulation of subcutaneous adipose tissue
and skin inflammation from baseline to Week 52) will be assessed using the same two 
primary  efficacy  variables, but measured at Week 52.
9.5.2 Safety  variables
The assessment of safety  will be based mainl y on the frequency  of adverse events and 
laboratory  data.  Other safet y data, including vital signs (blood pressure, weight, waist 
circumference, BMI), and clinical laboratory  variables (glucose, insulin, hs-CRP, HOMA- IR, 
HbA1c) will be summarized by strat um, as appropriate.
Adverse events will be summarized by presenting, for each treatment group, 
the number and 
percentage of patients having any  adverse event, having an adverse event in each body  system 
and having each individual adverse event.  Any other information collected (e.g., severity  or 
relatedness to s tudy medication) will be listed, as appropriate.
Adverse events and serious adverse events up to and including Week 12 visit will be included 
in the database for the analy sis at the primary  analysis time point (Week 12).  All Adverse 
events and serious adverse events will be included in the final database analysis (Week 5 3).
Laboratory  variables and other safet y variables will be summarized , as appropriate .
Analy sis of safet y data will be based on the Safet y Set.

Novartis Confidential Page 66
Amended Protocol Version 0 2 (Clean ) Protocol No.CAIN457AUS07
 
9.7 Interim analy ses
The database of this study  will be locked twice, first after the end of double -blind treatment 
period (Week 12) and again at the end of the follow -up period (Week 5 3).  Data analyses will 
follow each database lock.  The main analy sis for the primary  objective will be done at Week 
12.  As Week 12 analy sis considered primary  and no specific hypothesis is pre-identified for 
testing, adjustment of significance level due to this interim analy sis is irrelevant.
In addition, after all patients complete their baseline visit, the demographic and baseline 
characteristics may  be summarized to help design new studies.

Novartis Confidential Page 67
Amended Protocol Version 0 2 (Clean ) Protocol No.CAIN457AUS07
9.8 Sample size calculation
The table below considers total sample sizes of 75 patients (50 in secukinumab group and 25 
in placebo group) and 99 patient s (66 in secukinumab group and 33in placebo group) to 
estimate the difference between the two groups with respect to the pooled estimate of the two 
percentage sof patients who have the “event” at Week 12 for each of the two primary  efficacy
variables .  The entries in the table are the “margin of error” (half- width of confidence interval) 
for a two-sided 95% confidence interval (Julious and Patterson, 2004; Kianifard and Islam, 
2011; nQuery  Advisor 7.0).  
Table 9
-1 Sample size calculations for percentage of patients who have the 
“event”
Percentage with “event”Half-width of confidence 
interval for n = 75Half-width of confidence 
interval for n = 99
30% 25.0% 21.4%
40% 26.5% 22.7%
50% 27.0% 23.2%
60% 26.5% 22.7%
70% 25.0% 21.4%
Based on the results in the above table, it was decided that approximately  75 randomized 
patient s (50 in secukinumab group and 25 in placebo group) will be randomized in this 
exploratory  study to estimate the difference in response rates between the two treatment 
groups.   
10 Ethical considerations
10.1 Regulatory  and ethical compliance
This clinical study  was designed and shall be implemented, executed and reported in 
accordance with the ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with 
applicable local regulations (including European Directive 2001/20/EC, US CFR 21, and 
Japanese Ministry  of Health, L abor, and Welfare), and with the ethical principles laid down in 
the Declaration of Helsinki.
10.2 Informed consent procedures
Eligible patient smay only be included in the study  after providing written (witnessed, where 
required by law or regulation), IRB/IEC -approved informed consent, or, if applicable after 
such consent has been provided by a  legally  acceptable representative(s) of the patient .In 
cases where the patient ’s representative gives consent, the patient must be informed about the 
study  to the extent possible given his/her understanding. If the patient is capable of doing so, 
he/she must indicate assent by personall y signing and datin g the written informed consent 
document or a separate assent form. Informed consent must be obtained before conducting 
any study-specific procedures (e.g.,all of the procedures described in the protocol). The 
process of obtaining informed consent must b e documented in the patient ’ssource documents. 

Novartis Confidential Page 68
Amended Protocol Version 0 2 (Clean ) Protocol No.CAIN457AUS07
Novartis will provide to investigators in a separate document a proposed informed consent 
form that complies with the ICH GCP guideline and regulatory  requirements and is 
considered appropriate for this study. Any changes to the proposed consent form suggested 
by the investigator must be agreed to by Novartis before submission to the IRB/IEC, and a 
copy  of the approved version must be provided to the Novartis or CRO monitor after IRB/IEC 
approval.
10.3 Responsibi lities of the investigator and IRB/IEC
Before initiating a trial, the investigator/institution must obtain approval/favorable opinion 
from the Institutional Review Board/Independent Ethics Committee (IRB/IEC) for the trial 
protocol, written informed consen t form, consent form updates, patient recruitment 
procedures (e.g., advertisements) and any other written information to be provided to patient s.
Prior to study  start, the investigator is required to sign a protocol signature page confirming 
his/her agree ment to conduct the study  in accordance with these documents and all of the 
instructions and procedures found in this protocol and to give access to all relevant data and 
records to Novarti s monitors, auditors, Novartis Quality  Assurance representatives, designated 
agents of Novartis, IRBs/I ECs, and regulatory  authorities as required. If an inspection of the 
clinical site is requested by a regulatory  authority , the investigator must inform Novartis 
immediately  that this request has been made.
10.4 Publication o f study  protocol and results
The key design elements of this protocol will be posted in a publicly  accessible database such 
as clinicaltrials.gov. In addition, upon study  completion and finalization of the study  report 
the results of this trial will be either submitted for publication and/or posted in a publicly  
accessible database of clinical trial results.
10.5 Qualit y Control and Quality  Assurance
Novartis maintains a robust Quality  Management (QM) system that includes all activities 
involved in quality  assurance and qualit y control, including the assignment of roles and 
responsibilities, the reporting of results, and the documentation of actions and escalation of 
issues identified during the review of qualit y metrics, incidents, audits and inspections.
Audits of investigator sites, vendors, and Novartis sy stems are performed by  Novartis Pharma 
Auditing and Compliance Quality  Assurance, a group independ ent from those involved in 
conducting, monitoring or performing qualit y control of the clinical trial. The clinical audit 
process uses a knowledge/risk based approach.
Audits are conducted to assess GCP compliance with global and local regulatory  requirem ents, 
protocols and internal SOPs, and are performed according to written Novartis processes.
11 Protocol adherence
This protocol defines the study  objectives, the study  procedures and the data to be collected 
on study  participants. Additional assessments required to ensure safet y of patient sshould be 
administered as deemed necessary  on a case by case basis. Under no circumstances is an 

Novartis Confidential Page 69
Amended Protocol Version 0 2 (Clean ) Protocol No.CAIN457AUS07
investigator allowed to collect additional data or conduct any additional procedures for any 
research -related purpose involving an y investigational drugs under the protocol.
Investigators ascertain they will apply due diligence to avoid protocol deviations. If an 
investigator feels a protocol deviation would improve the conduct of the study  this must be 
considered a protocol amendment, and unless such an amendment is agreed upon by Novartis 
and approved by the IRB/IEC and health authorities, where required, it cannot be 
implemented. 
11.1 Protocol a mendments
Any change or addition to the protocol can onl y be made in a written protocol amendment that 
must be approved by Novartis, health authorities where required, and the IRB/IEC prior to 
implementation. Only amendments that are intended to eliminate an apparent immediate 
hazard to patient smay be implemented immediately  provided the health authorities are 
subsequently  notified by protocol amendment and the reviewing IRB/IEC is notified.
Notwithstanding the need for approval of formal protocol amendments, the investigator is 
expected to take any immediate action required for the safety of any patient included in this 
study , even if this action represents a deviation from the protocol. In such cases, the reporting 
requirements identified in Section 7 Safety  Monitoring must be foll owed.
12 References
References are available upon request
Chiricozzi, A., Guttman- Yassky , E., Suárez -Fariñas, M., Nograles, K., Tian, S., Cardinale, I., 
Chimenti, S. and Krueger, J. (2011). I ntegrative Responses to IL -17 and TNF -α in Human 
Keratinocy tes Account for Key  Inflammatory  Pathogenic Circuits in Psoriasis. Journal of 
Investigative Dermatology , 131(3), pp.677 -687.
Chiricozzi, A., Suárez -Fariñas, M., Fuentes -Duculan, J., Cueto, I ., Li, K., Tian, S., 
Brodmerkel, C. and Krueger, J. (2016). Increased expression of interleukin -17 pathway  genes 
in nonlesional skin of moderate -to-severe psoriasis vulgaris. Br J Dermatol , 174(1), pp.136-
145.
Chobanian, A., Bakris, G., Black, H., Cushman, W., Green, L., I zzo, J., Jones, D., Materson, 
B., Oparil, S., Wright, J. and Roccella, E. (2003). Seventh Report of the Joint National 
Committee for human medicinal products (CHMP), Europea n Agency  for the Evaluation of 
Medicinal Products (2004)] Guideline on Clinical I nvestigation of Medicinal Products 
Indicated for the Treatment of Psoriasis. EMEA, London.
Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure . 
Hypertension, 42(6), pp.1206-1252.
Czarnowicki, T., Esaki, H., Gonzalez, J., Malajian, D., Shemer, A., Noda, S., Talasila, S., 
Berry , A., Gray , J., Becker, L., Estrada, Y., Xu, H., Zheng, X., Suárez -Fariñas, M., Krueger, J., 
Paller, A. and Guttman -Yassky , E. (2015). Earl y pediatric atopic dermatitis shows only  a 
cutaneous l ymphocy te antigen (CLA)+ TH2/TH1 cell imbalance, whereas adults acquire 
CLA+ TH22/TC22 cell subsets. Journal of Allergy and Clinical Immunology , 136(4), pp.941 -
951.e3.

Novartis Confidential Page 70
Amended Protocol Version 0 2 (Clean ) Protocol No.CAIN457AUS07
Davidovici, B., S attar, N., Jörg, P., Puig, L ., Emery , P., Barker, J., van de Kerkhof, P., Ståhle, 
M., Nestle, F., Girolomoni, G. and Krueger, J. (2010). Psoriasis and Sy stemic I nflammatory  
Diseases: Potential Mechanistic L inks between Skin Disease and Co -Morbid Conditions. 
Journal of Investigative Dermatology , 130(7), pp.1785 -1796.
Dohert y, S., Van Voorhees, A., Lebwohl, M., Korman, N., Young, M. and Hsu, S. (2008). 
National Psoriasis Foundation consensus statement on screening for latent tuberculosis 
infection in patients with psoriasis treated with s ystemic and biologic agents. Journal of the 
American Academy of Dermatology , 59(2), pp.209-217.
Endo, Y., Asou, H., Matsugae, N., Hirahara, K., Shinoda, K., Tumes, D., Tokuy ama, H., 
Yokote, K. and Nakay ama, T. (2015). Obesity  Drives Th17 Cell Differentiation by  Inducing 
the L ipid Metabolic Kinase, ACC1. Cell Reports , 12(6), pp.1042 -
1055.
Fredriksson, T. and Pettersson, U. (1978). Severe Psoriasis –Oral Therap y with a New 
Retinoid. Dermatology , 157(4), pp.238 -244.
Gisondi, P., Cotena, C., Tessari, G. and Girolomoni, G. (2008). Anti–tumour necrosis factor -α 
therap y increases bod y weight in patients with chronic plaque psoriasis: a retrospective cohort 
study . Journal of the European Academy of Dermatology and Venereology , 22(3), p p.341-344.
Gottlieb, A., Griffiths, C., Ho, V., Lahfa, M., Mrowietz, U., Murrell, D., Ortonne, J., Todd, G., 
Cherill, R., Marks, I ., Emady -Azar, S. and Paul, C. (2005). Oral pimecrolimus in the 
treatment of moderate to severe chronic plaque
-type psoriasis: a double -blind, multicentre, 
randomized, dose-finding trial. Br J Dermatol , 152(6), pp.1219 - 1227.
Higa -Sansone, G., Szomstein, S., Soto, F., Brasecsco, O., Cohen, C. and Rosenthal, R. (2004). 
Psoriasis Remission after L aparoscopic Roux -En-Y Gastric By pass for Morbid Obesity . 
Obesity Surgery , 14(8), pp.1132 -1134.
HoJC., L ee CH. and Lin SH. (2016). No significant reduction of circulating endothelial -
derived and platelet- derived microparticles in patients with psoriasis successfully  treated with 
anti-IL-12/23. Biomed Res Int , 2016:2016, pp.1 -6.
Julious, S. and Patterson, S. (2004). Sample sizes for estimation in clinical research. 
Pharmaceut. Statist. , 3(3), pp.213
-215.
Kianifard, F. and Islam, M. (2011). A guide to the design and analy sis of small clinical studies. 
Pharmaceut. Statist. , 10(4), pp.363-368.
Łuczy ński, W., Grubczak, K., Moniuszko, M., Głowińska-Olszewska, B. and Bossowski, A. 
(2015). Elevated levels of Th17 cells in children with central obesit y. Scandinavian Journal of 
Clinical and Laboratory Investigation , 75(7), pp.595-601.
Manuel, O. and Kumar, D. (2008). QuantiFERON ® - TB Gold assay  for the diagnosis of 
latent tuberculosis infection. Expert Review of Mo lecular Diagnostics , 8(3), pp.247 -256.
Mehta, N. (2011). S ystemic and Vascular Inflammation in Patients With Moderate to Severe 
Psoriasis as Measured b y [18F] -Fluorodeox yglucose Positron Emission Tomograph y –
Computed Tomograph y (FDG -PET/CT). Arch Dermatol ,147(9), p.1031.
Naik, H., Natarajan, B., Stansky , E., Ahlman, M., Teague, H., Salahuddin, T., Ng, Q., Joshi, 
A., Krishnamoorth y, P., Dave, J., Rose, S., Doveikis, J., Playford, M., Prussick, R., Ehrlich, 
A., Kaplan, M., Lockshin, B., Gelfand, J. and Mehta , N. (2015). Severity  of Psoriasis 
Associates With Aortic Vascular Inflammation Detected b y FDG PET/CT and Neutrophil 

Novartis Confidential Page 71
Amended Protocol Version 0 2 (Clean ) Protocol No.CAIN457AUS07
Activation in a Prospective Observational Study Significance. Arterioscler Thromb Vasc Biol , 
35(12), pp.2667-2676.
Naldi, L ., Chatenoud, L. , Linder, D., Belloni Fortina, A., Peserico, A., Virgili, A., Bruni, P., 
Ingordo, V., Scocco, G., Solaroli, C., Schena, D., Barba, A., Di Landro, A., Pezzarossa, E., 
Arcangeli, F., Gianni, C., Betti, R., Carli, P., Farris, A., Barabino, G. and Vecchia, C. (2005). 
Cigarette Smoking, Bod y Mass I ndex, and Stressful L ife Events as Risk Factors for Psoriasis: 
Results from an I talian Case –Control Study . Journal of Investigative Dermatology , 125(1), 
pp.61-67.
Pickering, T., Hall, J., Appel L ., Falkner, B., Graves, J., Hill, M., Jones, D., Kurtz, D., Sheps, 
S., Roccella, E. (2005). Recommendations for blood pressure measurement in humans and 
experimental animals: Part 1: Blood pressure measurement in humans. Circulation , 111, 
pp.697-716.
Reis, B., Lee, K., Fanok, M., Mascaraque, C., Amoury , M., Cohn, L., Rogoz, A., Dallner, O., 
Moraes -Vieira, P., Domingos, A. and Mucida, D. (2015). Leptin Receptor Signaling in T 
Cells I s Required for Th17 Differentiation. The Journal of Immunology , 194(11) , pp.5253-
5260.
Renzo, L ., Saraceno, R., Schipani, C., Rizzo, M., Bianchi, A., Noce, A., Esposito, M., Tiberti, 
S., Chimenti, S. and De Lorenzo, A. (2011). Prospective assessment of body  weight and body  
composition changes in patients with psoriasis receiv ing anti -TNF -
α treatment. Dermatologic 
Therapy , 24(4), pp.446- 451.
 
 
Saraceno, R., Schipani, C., Mazzotta, A., Esposito, M., Direnzo, L ., Delorenzo, A. and 
Chimenti, S. (2008). Effect of anti -tumor necrosis factor -α therapies on body  mass index in 
patients with psoriasis. Pharmacological Research , 57(4), pp.290-295.
Stokes, M., Davis, C. and Koch, G. (2012). Categorical data analysis using the SAS system, 
third edition . Cary , NC: SAS I nstitute.
Tan, E., Baker, C. and Foley , P. (2013). Weight gain and tumour necrosis factor -alpha 
inhibitors in patients with psoriasis. Australasian Journal of Dermatology , 54(4), pp.259-263.
Wang, C., Suárez -Fariñas, M., Nograles, K., Mimoso, C., Shrom, D., Dow, E., Hef fernan, M., 
Hoffman, R. and Krueger, J. (2014). IL -17 Induces I nflammation -Associated Gene Products 
in Blood Monocy tes, and Treatment with I xekizumab Reduces Their Expression in Psoriasis 
Patient Blood. Journal of Investigative Dermatology , 134(12), pp.2990- 2993.
Weisman, S., Pollack, C. and Gottschalk, R. (2003). Psoriasis disease severity  measures: 
comparing efficacy  of treatments for severe psoriasis. Journal of Dermatological Treatment, 
14(3), pp.158-165.
Wolters, M. (2005). Diet and psoriasis: experimental data and clinical evidence. Br J 
Dermatol , 153(4), pp.706-714.
Zaba LC, Cardinale I, Gilleaudeau P, et al. (2007). Amelioration of epidermal hy perplasia by  
TNF inhibition is associated with reduced Th17 responses. J Exp Med; 204:3183–3194.

Novartis Confidential Page 72
Amended Protocol Version 0 2 (Clean ) Protocol No.CAIN457AUS07
Zaba LC, Krueger JG, Lowes MA (2009) Resident and "inflammatory " dendritic cells in 
human skin. J Invest Dermatol ; 129:302 –308.

Novartis Confidential Page 73
Amended Protocol Version 0 2 (Clean ) Protocol No.CAIN457AUS07
13 Appendix 1: Clinically  notable laboratory  values and vital 
signs
The following criteria will be used to define expanded limits and notable abnormalities of key 
laboratory  tests.   Notable values for blood pressure and pulse are presented in Section 6.7.2.
Nospecific action ispre-defined within thisprotocol torespond t ospecific notable laborator y
or vital signs values . It will bedecided bythe investigator/qualified sitestaff
whether and which specific action needs to be taken to respond to anynotable values, taking 
into account the overall status of the patient .
Liver function and related variables
ALT (SGPT) > 3 x Upper Limit of Normal (ULN)
AST (SGOT) > 3 x ULN
Total bilirubin > 1.5 x ULN
Alkaline phosphatase > 2 x ULN
Renal function
Creatinine (serum) > 1.5 x ULN
Hematology  variables
Hemoglobin ≥ 2.0 g/dL decrease from baseline
Platelet count < Lower Limit of Normal (LLN)
White blood cell < 0.8 x LLN
Neutrophils < 0.9 x LLN
Eosinophils > 1.1 x ULN
Lymphocytes: > 1.1 x ULN

Novartis Confidential Page 74
Amended Protocol Version 0 2 (Clean ) Protocol No.CAIN457AUS07
14 Appendix 2: Tuberculosis screening flowchart

Novartis Confidential Page 75
Amended Protocol Version 0 2 (Clean ) Protocol No.CAIN457AUS07

Novartis Confidential Page 76
Amended Protocol Version 0 2 (Clean ) Protocol No.CAIN457AUS07

Novartis Confidential Page 77
Amended Protocol Version 0 2 (Clean ) Protocol No.CAIN457AUS07

Novartis Confidential Page 78
Amended Protocol Version 0 2
(Clean ) Protocol No.CAIN457AUS07
16 Appendix 4:  Psoriasis A rea and Severity  Index (PA SI) and 
Body Surface A rea (BSA )

Novartis Confidential Page 79
Amended Protocol Version 0 2 (Clean ) Protocol No.CAIN457AUS07
17 Appendix 5:  Sample Log Table
Sample log time schedule for sampling for  adipose tissue, 

Novartis Confidential Page 80
Amended Protocol Version 0 2 (Clean ) Protocol No.CAIN457AUS07
WeekVisit 
No. Time PointBlood - 
Microparticle s 
& Le ukocy tes 
(FACS - 
ambient)Blood - 
Microparticle s 
& Le ukocy tes 
(FACS - 
ambient)Blood - 
Microparticle s 
& Le ukocy tes 
(FACS - froz en)Blood - 
Microparticle s 
& Le ukocy tes 
(FACS - froze n)
Sample #
Scre ening 1 Weeks -4 to Bas eline
Baseline 2 predos e 10 m L 601 10 m L 605
Week 1 (D ay 8) 3
Week 2 (D ay 15) 4
Week 3 (D ay 22) 5
Week 4 (D ay 29) 6 predos e
Week 8 (D ay 57) 7
Week 12 (Day 85) 8 predos e 10 m L 602 10 m L 606
Week 13 (Day 92) 9
Week 16 (Day 113) 10
Week 24 (Day 169) 11 predos e 10 m L 603 10 m L 607
Week 32 (Day 225) 12
Week 40 (Day 281) 13
Week 48 (Day 337) 14
Week 52 (Day 365) 15 10 m L 604 10 m L 608
Week 53 (Day 372)
Total m L: 40 40
Consolidate d total m L:147.5

Novartis Confidential Page 81
Amended Protocol Version 0 2 (Clean ) Protocol No.CAIN457AUS07
